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ABSTRACT 
 
Cordes, Amanda Ann (Ph.D., Chemical and Biological Engineering) 
Complex Stability Behavior in Novel Protein Constructs: Aggregation of Fc- and HSA- Based 
Fusion Proteins 
Thesis directed by Professor Theodore W. Randolph 
 
The development of protein based biopharmaceuticals has resulted in the ability to treat 
many serious conditions, including endogenous protein deficiencies, cancer and autoimmune 
disorders. However, in order to be successful drug candidates, these more complex molecules 
require stable formulations that can last from manufacturing through transportation to patient 
administration. Fusion proteins, which are constructed from unrelated proteins or protein 
domains, present additional formulation challenges. In these proteins, domains did not co-evolve 
for stability and thus conditions favoring the stability of one domain may destabilize the other.  
Our current hypotheses are that the least stable protein will also be the least stable 
domain in the fusion and that selective stabilization of this least stable domain can be used to 
reduce overall aggregation of the fusion protein, with preferential binding of cosolutes to the 
native state being one method of achieving selective domain stabilization.  
Abatacept, an Fc-CTLA4 fusion protein, is used as a model to investigate the stability 
behavior of Fc fusion proteins. Fc-CTLA4 exhibits markedly different aggregation rates with 
only a small shift in pH. Changing from pH 7.5 to pH 6 causes a two order of magnitude increase 
in rate of monomer loss during incubation at 40 °C. The aggregation behavior during accelerated 
stability studies at elevated temperature was found to be controlled by conformational instability 
of the protein. Conditions which destabilized the CTLA4 domain and the CH2 portion of the Fc 
domain lead to a decreased activation energy for aggregation and an increased aggregation rate.  
iv 
 
Fc-CTLA 4 was also studied to examine how conditions which increase conformational 
stability impact the progression of aggregation due to other physical stresses (e.g., exposure to 
air/water and water/ice interfaces and freeze concentration during freezing). No changes were 
detected in the amount of monomer lost or number of particles formed between solution 
conditions at pH 6.0 and pH 7.5, despite large differences in conformational stability under these 
solution conditions.  
Two HSA fusion proteins (HSA-hGH and HSA-GCSF) were studied to investigate small 
molecule ligand binding as a selective stabilization strategy, with octanoic acid used as the 
ligand. Addition of octanoic acid resulted in increased conformational stability for HSA, HSA-
hGH and HSA-GCSF. Repulsive protein-protein interactions were only increased for HSA and 
HSA-hGH; HSA-GCSF protein-protein interactions remained unchanged. Reductions in 
aggregation were seen in the case of HSA-hGH. Thus it appears that specific binding to a 
domain of a fusion protein can reduce aggregation in more than one way (i.e. increasing both 
colloidal and conformational stability). No changes in HSA-GCSF aggregation were observed 
with the addition of octanoic acid, despite the increases in conformational stability, indicating the 
ligand binding stabilization approach does not appear to be applicable to all HSA fusions.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 General Background 
Therapeutic proteins currently provide a means of treatment for many serious diseases, 
including autoimmune disorders, endogenous protein deficiencies and cancer
 1
. These proteins 
are complex molecules that require not only the correct amino acid sequence, but also the correct 
folded three dimensional structures and higher order assembly state in order to function. Due to 
these requirements for a therapeutic protein, protein stability is an important area of research.  
The primary structure of a protein consists of the polypeptide chain of amino acids linked 
by peptide bonds. Each amino acid contains a central carbon atom with an amino group, a 
carboxyl group, a hydrogen atom and a unique side chain. Hydrogen bonding between the N-H 
and C=O bonds in the protein backbone lead to secondary structure motifs including alpha 
helices, beta sheets and random coils
 2
. Side chain interactions then determine how the protein 
folds into its tertiary structure. Some of this is driven by the ordering of hydrophobic groups on 
the interior of the protein and hydrophilic groups at the surface, but van der Waals forces, salt 
bridges and covalent disulfide bonds all contribute to tertiary structure. Quaternary structure is 
the arrangement of non-covalent subunits to create the active form of the protein. The simplest 
quaternary structure is a dimer, consisting of two folded monomer subunits. Aggregation is 
typically defined as non-native association and thus proteins exhibiting native quaternary 
structure would not be considered aggregates.  
The stability of proteins is a complex, multifaceted topic, but it can be roughly divided 
into two areas: chemical stability and physical stability
 3
. The chemical stability relates to 
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reactions that can change the composition of the protein, such as deamidation, oxidation, beta 
elimination and glycation
 3
. Fragmentation of the polypeptide chain as well as disulfide bond 
cleavage or shuffling are other pathways of chemical degradation.  In a deamidation reaction, an 
asparagine or glutamine amino acid is converted to aspartic or glutamic acid, respectively. 
Glycation involves the reaction of a reducing sugar with a basic amino acid to form a Schiff 
base. Oxidation can damage the side chains of many amino acids including histidine, methionine, 
cysteine, tryptophan and tyrosine.  Formulation conditions can be chosen to minimize the above 
chemical instabilities
 3
. For example, both deamidation and oxidation can be influenced by 
changing the solution pH. Glycation can be reduced by the choice of appropriate excipients, 
which in this case would be non-reducing sugars such as sucrose or trehalose rather than 
reducing sugars such as glucose, fructose or maltose
 3.
  
For a protein to be considered physically stable, it must maintain the proper three-
dimensional folded structure as well as the correct higher order assembly state, which is typically 
monomer for therapeutic proteins. The conformational stability, or the stability of the folded 
protein structure, is quantified by the free energy of unfolding, ΔGunf
 3
, and is determined by 
intramolecular interactions. It can be measured using thermally-induced protein unfolding 
(monitored with differential scanning calorimetry or circular dichroism) or chaotrope-induced 
unfolding with urea and guanidine hydrochloride (monitored with fluorescence spectroscopy or 
circular dichroism). Colloidal stability is determined by intermolecular interactions. In 
colloidally-stable systems, repulsive intermolecular interactions inhibit aggregation
 4
. These 
interactions are reflected in protein osmotic second virial coefficients for the buffer systems 
(B22); repulsive intermolecular interactions result in positive values of B22. During formulation 
development, the colloidal and conformational stability of proteins in potential formulations is 
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assessed to determine the most stable solution conditions for a given protein
 5.
 Accelerated 
stability studies expose the protein formulations of interest to a variety of stresses, such as 
elevated temperature or agitation, to obtain the aggregation results more rapidly than is possible 
for solutions under normal protein storage conditions
 6
. Formulation conditions for single domain 
proteins are aimed at maximizing both B22 and ΔGunf. 
The first two steps of the protein aggregation pathway are depicted in the Lumry-Eyring 
framework as a conformational change from a native-like conformation to an aggregation 
competent conformation and then association of these aggregation competent species into an 
initial aggregate
 7, 8, 9
, as shown in Figure 1-1. It is important to note that complete unfolding of 
the protein is not required to produce an aggregation competent species and that the initial 
aggregates formed during the association step may be reversible. When these steps are depicted 
on a reaction energy diagram (Figure 1-2), there is an associated activation energy barrier for 
each step in the aggregation pathway. Increasing the energy of the intermediate aggregation 
competent state, reflected by an increased free energy of unfolding (ΔGunf), increases the 
activation energy barrier for step one. The protein-protein interactions are related to the height of 
the second barrier, with more repulsive protein-protein interactions raising the activation energy 
for association.  
For the initial steps in a given protein aggregation pathway, either conformational or 
colloidal stability can be rate limiting
 8, 9
. In cases where the aggregation appears to be first order, 
a unimolecular event (i.e. unfolding) likely governs the aggregation and increasing 
conformational stability can reduce said aggregation. If the association step is rate limiting, the 
reaction may appear to be second order or higher, depending on the size of the initial aggregate. 
Modulating protein-protein interactions to make them more repulsive can reduce the reaction  
4 
 
 
 
 
 
 
 
Figure 1-1: The initial steps in the protein aggregation pathway. Step one is a conformational 
change to an aggregation competent conformation and step two is the reversible association of 
two aggregation competent species to form an initial aggregate.  
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Figure 1-2: Reaction energy diagram of the first two steps in the protein aggregation pathway. In 
this figure, N represents the native conformation of the therapeutic protein and I is an 
aggregation competent conformation different from that of the native state. Agg represents the 
initial aggregate typically, although not always, composed of two I monomers. 
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rates in these cases
 8, 9
. The apparent reaction order may also be concentration dependent, 
switching from an apparent first order to an apparent second order reaction with changes in 
concentration
 10
.  
The changes to chemical stability can have an impact of physical stability and vice versa. 
An example of this interdependence is illustrated in the situation of proteins that aggregate 
physically then undergo reactions to become covalently linked by disulfide bonds. Oxidation has 
also been shown to reduce the conformational stability of proteins
 11
. In some cases it can be 
difficult to balance the requirements between physical and chemical stability. For example, the 
deamidation rate is typically at a minimum between pH 3 and pH 6
 3
, but depending on the pI of 
the protein, it may not be possible to formulate there due to solubility concerns.  
Since aggregation is taken to mean any non-native protein association, protein aggregates 
encompass a wide range of sizes and possible morphologies as the aggregation proceeds beyond 
the initial steps. After the initial conformational perturbation and association steps, the following 
steps involve a conformational rearrangement of the protein to create an irreversible aggregate 
and the growth to larger aggregate sizes
 9
. During aggregation, steps may be occurring in 
parallel, and not every step will necessarily be involved in the aggregation pathway for a given 
protein
 9
. The smallest possible protein aggregate is a dimer, composed of two monomeric 
protein units. Smaller oligomers, including dimers up to aggregates of 0.1 um, are generally 
considered to be soluble aggregates. Here the term “soluble” indicates the aggregates are 
detectable by size exclusion chromatography (SEC) and are not large enough to be filtered out 
by the resin of the guard column or pelleted during centrifugation prior to SEC analysis
 12
. 
Aggregates not detectable by traditional SEC methods are considered “insoluble”. This includes 
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protein particles in the visible and sub visible ranges. Depending on the aggregation pathway, 
protein aggregates may be amorphous or may form more ordered fibril structures
 9
.  
Because therapeutic proteins require the proper folded structure and assembly state to be 
active, developing a stable formulation for these products is important. By selecting the optimal 
buffer conditions and excipients, it is possible to create products with the appropriate shelf life 
and the ability to withstand potential sources of damage so that the drug can be safely 
administered to the patient. Salt concentrations and pH conditions might be chosen to optimize 
colloidal stability by changing protein-protein interactions. Examples of this include using salts 
to provide charge shielding for attractive protein-protein interactions or formulating at a pH 
value some distance from the pI, where the protein will have a greater net charge and presumable 
more repulsive protein-protein interactions. Preferentially excluded excipients, such as sucrose, 
are included in formulations due to the increased conformational stability they provide
 13
. Non-
ionic surfactants such as polysorbate 20 are also added to protect protein products from damage 
due to agitation
 14
. 
In addition to the physical and chemical stability considerations involved when 
developing a formulation, there are also commercial factors at play. Liquid formulations are 
preferred over lyophilized formulations and there has recently been a push towards products in 
pre-filled syringes that can be administered at home
 15
. These different requirements necessitate 
an understanding of the unique protein degradation pathways so each formulation can be 
designed to reduce protein degradation.  
Therapeutic protein products are exposed to conditions which can compromise their 
stability and potentially induce aggregation during all stages of the product life cycle
 16, 17, 18
. 
During manufacture, interaction with surfaces such as membranes during a filtration step can 
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cause aggregation
 19
. Pumps may shed microparticles to which proteins then adsorb. Pumps can 
also cause cavitation and the air/water interface created during this cavitation can damage 
proteins
 17
. Agitation during shipping can also damage protein, most likely through the increased 
amount of air-water interface turnover caused by the shaking. During storage, the proteins can 
interact with container materials, such as silicon oil in pre-filled syringes or vial stoppers, and 
these materials, or leachates from these materials, can interact unfavorably with the proteins
 17
. 
Finally, proteins may be exposed to changes in temperature during storage, including the 
possibility of undergoing freeze-thaw cycles when stored for use at home
 20
. Thus it is important 
to develop a robust formulation to help protect proteins from these stresses which may alter the 
protein conformation or assembly state in such a way that reduces product quality or 
performance. Consequences of this instability include loss of product and the resulting loss of 
profit from being unable to sell this product.  
More seriously, there are concerns for patient welfare if the aggregated product is 
injected into a patient. The drug efficacy may not be at the desired levels if the active sites of the 
molecule are compromised when the protein forms an aggregate
 21
. Previous research also 
suggests that the repetition of ordered epitopes (such as those present in aggregates) facilitates an 
immune response
 22
. If the therapeutic protein is being delivered as a replacement for endogenous 
protein, the immune response can generate neutralizing antibodies which may not only render the 
drug ineffective but also have the potential to cross-react with the native protein. Neutralizing 
antibodies have been implicated in the case of patients treated with recombinant epoetin alpha 
who experienced pure red cell aplasia, where their levels of endogenous erythropoetin were 
essentially reduced to zero
 23, 24
. Repetitive blood transfusions were then required to treat the 
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patients.
 
The treatment of hemophilia by administration of factor VIII is also affected by the 
presence of anti-drug antibodies induced by the drug product
 25
.  
Recently the presence of particles in formulations has been linked to the creation of an 
adverse immune response
 22, 26
, particularly particles in the 1-10 μm range which are 
hypothesized to be especially effective at triggering this immune response. The current guidance 
on the acceptable level of particles in the final product comes from the United States 
Pharmacopeia (USP) and was based on traditional small molecule drugs. The guidelines were 
primarily focused the risk patients faced from capillary occlusion caused by the particles, and not 
on the potential for immunogenicity
 27
. In addition, the specifications are for the number of 
particles larger than 10 μm and larger than 25 μm, which may not be the size range of concern 
for product immunogenicity.  
There are many sources of non protein particles from the manufacturing process, 
including cellulose from filters, metal particles shed from pumps, and in the case of pre-filled 
syringes, silicone oil droplets from the syringes and tungsten from the needle attachment
 28, 29
. 
Protein can adsorb onto these particles, presenting ordered, spaced epitopes of the therapeutic 
protein for detection by the immune system. The particles may also be formed from aggregated 
protein product alone. Protein formulations can be designed to stabilize the proteins against 
interactions with the foreign particles and to reduce the formation of larger protein particles.  
Further complicating the study of particles is the difficulty in detecting and analyzing 
these particles in solution, due to their size and potentially low levels. The current USP method 
for detection of particles is based on light obscuration. While this method can indicate the size of 
the particles, it provides no information on the particle composition, making it less useful for 
root cause analysis and determination of the source of particles
 27
. There is support developing 
10 
 
for micro flow imaging techniques as an orthogonal method to light obscuration. This technique 
allows one to determine not only the size but also the morphology and optical properties of the 
particles in solution
 30
. Micro flow imaging can detect and characterize particles in the 1-10 um 
size range and help to determine the composition of the particles
 27
, which then allows one to 
take a more directed strategy to prevent the formation of these particles.  
For all of the above mentioned reasons involving patient safety, cost, time and 
profitability, it is important to understand and control protein aggregation. Robust formulations 
which stabilize the protein against a variety of stresses help ensure a safe product for the patient. 
Additional understanding of the driving forces of aggregation can help improve future 
formulations.  
  
1.2 Fusion Protein Background 
For the scope of this thesis, a fusion protein is defined as an artificial construct combining 
unrelated proteins or domains from those proteins (Figure 1-3). The domains are not covalently 
bound together; rather, the DNA coding each protein/domain is expressed together as a single 
polypeptide. Fusion proteins are a growing class of therapeutic molecules, with several FDA 
approved products and many more in late stage development
 31
. The fusion protein notation used 
here is in the form of X-Y, where X and Y are the proteins or protein domains combined to 
create the fusion and X-Y is the resulting fusion protein product.  
There are many potential fusion protein partners, including the Fc or Fab antibody domains
 
31, 32
, human serum albumin (HSA), transferrrin, C-terminal peptide of hCG, and heparin
 33
,  
although all of the FDA approved fusion protein products currently on the market fall into the Fc 
fusion class. HSA fusion constructs including human serum albumin-human growth hormone as  
11 
 
 
 
 
 
 
 
Figure 1-3: Schematic of a generic fusion protein. In this figure, Protein A and Protein B are 
unrelated proteins, or domains from unrelated proteins. The A-B fusion protein is the resulting 
product when Protein A and Protein B are expressed together in a single polypeptide chain.  
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well as human serum albumin-granulocyte colony stimulating factor have been investigated in 
clinical trials, although neither was approved by the FDA.  
The Fc fusion class is based on human antibodies. Antibodies are composed of two heavy 
chains and two light chains, depicted in Figure 1-4, with the heavy chain being approximately 
twice the molecular weight of the light chain
 2
. The heavy chains are connected by disulfide 
bonds in the hinge region between the Fc and Fab domains. Each light chain has a variable 
region and a constant region, while the heavy chain has a variable region and three constant 
regions (CH1, CH2 and CH3). The Fab (fragment antigen binding) domain is composed of the 
light chain as well as the heavy chain variable region and constant region
 2
. The Fc (fragment 
crystallizable) domain consists of the CH2 and CH3 regions of the two heavy chains and has a 
molecular weight of approximately 50 kDa. It is the Fc domain which is the current partner in all 
of the approved fusion proteins.  
Human serum albumin (HSA) is another fusion partner of interest. HSA is a primarily 
alpha helical (approximately 67% by x-ray diffraction) protein
 34
. It is composed of 585 amino 
acids and has a molecular weight of 67 kDa. In the body, HSA binds a wide variety of 
compounds including small molecule drugs, fatty acids, steroids and metal cations including 
copper (II), calcium, magnesium and zinc
 34
. The entirety of the HSA protein is used a fusion 
partner, unlike Fc based fusions which use only a portion of the antibody. 
Fusion proteins are of interest commercially because there can be additional benefits 
from combining the therapeutic protein of interest with HSA or with the Fc domain compared to 
the therapeutic protein alone. Both Fc and HSA fusions increase the circulation half life of the 
partnered domain
 32, 35, 36, 37
, reducing the required frequency of drug administration which is 
beneficial from a patient compliance perspective
 38, 39
. An Fc fusion can also have additional  
13 
 
 
 
 
 
Figure 1-4: Antibody structure. Antibody molecules are composed of two heavy chains and two 
light chains. The Fab domain is composed of the light chains and a portion of the heavy chains. 
The Fc domain consists of the CH2 and CH3 regions of the heavy chains.  
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functionality related to the activity of the Fc domain including inducing antibody dependent cell 
mediated cytotoxicity or triggering the release of inflammatory cytokines
 32
. If this additional 
functionality is not desired, the Fc domain can be mutated in order to remove its biological 
activity
 40
. In such cases, the benefit of the increased circulation half life would still remain.  
 
1.3 Challenges specific to fusion proteins 
 
Formulation strategies may become more complicated with fusion proteins. Unlike 
natively occurring proteins, the domains in fusion proteins have not co-evolved. Thus, they may 
lack stabilizing intra-domain interactions. Furthermore, conditions which lead to repulsive 
interactions between molecules (increased colloidal stability, more negative B22) may also cause 
repulsive intramolecular interactions between the domains resulting in reduced conformational 
stability (lower ΔGunf).  
Another challenge is predicting the aggregation/stability behavior of the new fusion 
protein construct from that of the two original domains. Each individual domain has its own level 
of conformational stability, reflected in the ΔGunf, and colloidal stability as determined by the 
protein-protein interactions. Since the unfolding of a domain within a protein may proceed 
independently of another domain
 41, 42, 43
 and since there may not necessarily be stabilizing 
intradomain interactions between the unrelated fusion domains, domain conformational 
instability has the potential to be a major driving force for fusion protein aggregation. If no 
significant intradomain interactions occur when the fusion is created, the domain conformational 
stability of the original proteins may remain unchanged in the fusion, allowing a priori 
determination of the least stable domain.   
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 However, colloidal stability of the individual domains is not expected to be predictive of 
the colloidal stability of the overall fusion protein. The colloidal stability is a function of two 
body interactions, which can give rise to non-ideal solution behaviors. The B22 (or second 
osmotic virial coefficient) is a measure of these non-ideal behaviors and can indicate whether 
protein-protein interactions are attractive (negative B22) or repulsive (positive B22)
 44
. It can be 
derived from statistical mechanics for spherically symmetric forces
 45
 as seen in the following 
equation: 
 
     
  
  
               
 
 
    
M= protein molecular weight 
R= intermolecular separation distance 
u(r) = interaction potential 
K = Boltzmann constant 
T = absolute temperature 
 
Hard sphere, electrostatic, van der Waals and other short range forces are all included in the 
interaction potential, u(r). 
In addition to including the hard sphere, electrostatic and van der Waals forces, B22 
values are impacted by charge distribution and protein geometry
 46
. Thus the B22 values for a 
fusion protein are not expected to be additive based on the B22 values of the domains since both 
charge distribution and geometry could differ between the original domains and the new fusion. 
Furthermore, B22 values are determined for the entire protein; there is no measure of colloidal 
stability for a domain in a protein. As mentioned previously, it is possible for the unfolding of 
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domains within a protein to be independent, illustrating the qualitative difference in the 
parameters.  
B22 behavior of the original domains and the fusion protein might correlate, but there is 
no basis to assume the B22 values of the original domains are predictive. For example, consider 
the case of creating a fusion from two domains, one with a +10 net charge and one with a -10 net 
charge. The electrostatic contribution to the B22 is described by the following equation
 47
: 
 
                   
  
          
 
 
where Z is the effective charge, M is the molecular weight, ρs is the solvent density and mions is 
the ion molal concentration. For both proteins, the electrostatic contribution to the B22 is positive. 
However, when the domains are combined in the fusion protein, the +10 net charge and the -10 
net charge would not only reduce the electrostatic contribution with a new apparent charge of 0, 
but also could create a dipole on the overall molecule, increasing the likelihood of attractive 
protein-protein interactions. This would not have been apparent from the B22 values for the 
parent domains.  
 
1.4 Objectives 
 
Due to the increasing number of therapeutic fusion proteins, it is desirable to have an 
increased understanding of domain contributions to overall fusion protein behavior, in order to 
approach formulation of these molecules in a rational manner. To this end, we have developed 
two hypotheses. First, we hypothesize that the overall stability and aggregation of multi-domain 
proteins can be controlled by choosing formulation conditions that favor the stability of the least 
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conformationally stable subunit. Second, we hypothesize selective stabilization of this domain 
will reduce overall aggregation of fusion construct.  
In this work, we use a model Fc-fusion and a model HSA-fusion to test the hypotheses 
and determine the impact of subunit stability on overall protein stability. The primary goal of the 
Fc-fusion study was to characterize the aggregation of this fusion and determine the driving 
forces. The goal of the HSA fusion studies was to not only examine the ways in which subunit 
stability influences the overall stability but also to determine if a formulation stabilization 
strategy could be developed that works across the HSA fusion protein class. To accomplish this, 
both conformational and colloidal stability studies of the complete fusion were performed, as 
well as stability studies of the HSA and hGH proteins alone, when possible. During these studies, 
cosolute binding was investigated as a way to achieve selective HSA domain conformational 
stabilization through the preferential binding of the cosolutes to the native state
 8.
 
This small molecule ligand binding as a selective domain stabilization strategy is based 
on the Wyman linkage function: 
 
 
    
     
       
        
          
 
In this equation, K is the equilibrium constant, ax is the activity of the ligand, vx
prod 
and vx
react
 are 
the numbers of ligand bound to the product and the reactant respectively and Δvx is the difference 
in number of bound ligand
 48, 13
. The gradient of the equilibrium constant with respect to ligand 
activity is related to the change in ligand binding between product and reactant; ligand binding 
will shift the equilibrium to the state with the greatest ligand binding. Since it is presumed that 
the protein will need a more native structure in order to bind the ligand, ligand binding should 
18 
 
drive the equilibrium towards a more native and less aggregation competent conformation. 
During the experiments, the stability of HSA and the HSA-fusion protein were compared in the 
presence and absence of the ligand. Octanoic acid was chosen as the primary stabilizing ligand. 
It is a known ligand of HSA, binding to subdomain IIIA and was used historically to prevent 
precipitation during the elevated temperature viral inactivation step during the purification of 
HSA from human sources
 34, 49, 50
. 
 In the case of the more pharmaceutically relevant Fc-fusion, once the driving forces for 
aggregation were determined, formulations that reduced monomer loss during elevated 
temperature studies were investigated for their ability to reduce aggregation under other 
conditions. Agitation and freeze/thawing were selected as additional stresses for the Fc-fusion 
since these stresses are also encountered over the life-cycle of a protein therapeutic
 17
. Particle 
formation under the different conditions was also examined. 
Overall conclusions about stability and recommendations for the HSA class are included.  
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CHAPTER 2 
 
FACTORS CONTRIBUTING TO THE AGGREGATION OF A THERAPEUTIC FC-
CTLA4 FUSION PROTEIN 
 
(A portion of this work has been published in the journal Biochemistry and appears as Jonas L. 
Fast, Amanda A. Cordes, John F. Carpenter, Theodore W. Randolph. Physical Instability of a 
Therapeutic Fc Fusion Protein: Domain Contributions to Conformational and Colloidal Stability. 
Biochemistry 2009, 48, 11724-11736.) 
 
 
2.1 Introduction 
Although there are multiple different fusion platforms in development, all of the currently 
approved fusion proteins are Fc fusions
 1. These are proteins in which the “fragment 
crystallizable” of an antibody is used as one half of the therapeutic fusion. Enbrel®, NPlate®, 
Orencia
®
 and Arcalyst
®
 are all examples of current Fc fusion products, and there are others in 
late stage clinical trials
 2
. Fc fusions are an attractive platform for several reasons. First, the 
addition of the Fc domain to a protein of interest increases the molecular weight of the 
therapeutic product compared to the original protein
 3
. This in turn can increase the circulation 
half-life of the drug. Second, the addition of the Fc domain can confer additional functionalities 
on the overall fusion product, since the antibody Fc domain is biologically active
 3, 4
. Increased 
understanding of the stability behavior of Fc fusion proteins is thus desirable due to the potential 
growth of this therapeutic class and its platform nature, where the Fc domain may be conserved 
as a partner in multiple fusions
 5
.  
For this work, Orencia
®
 (abatacept) was chosen as a model fusion protein. Orencia
®
 is 
composed of a human IgG1 Fc domain fused with the extracellular domain of CTLA4 (human 
cytotoxic T-lymphocyte associated factor)
 6
. There are two amino acid chains connected by a 
disulfide bond in the hinge region, with each chain having an Fc portion and a CTLA4 portion
 7
. 
Mutations in the CH2 region of the Fc domain were used to remove the biological activity of the 
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Fc domain
 4
. A model of the Fc-CTLA4 structure is shown in Figure 2-1. This therapeutic is 
approved for the treatment of rheumatoid arthritis and is formulated as a lyophilized powder.  
 The overall pI of Fc-CTLA4 is between 4.5-5.5, due to the variations in glycosylation. 
However, the theoretical pI values for each domain are very different. The theoretical pI for the 
CTLA4 domain is approximately 4.39 and the theoretical pI for the Fc domain is 7.16, based on 
SwisProt predictions from the amino acid sequence
 8, 9
. The therapeutic protein is formulated at 
pH 7.2, which fits with the traditional formulation approach, based on the overall pI of the 
molecule. At this pH, the CTLA4 domain would be expected to have a fairly high net charge, 
leading to possible repulsive interactions between CTLA4 domains. The Fc domain likely has 
very little charge at the formulation pH, and thus the protein-protein interactions would not be as 
strongly repulsive between these domains. If the pH was shifted from the formulation pH to pH 
6, which is between the two theoretical pI values for the individual domains, the domains would 
then have opposite charges. This could potentially create an overall dipole on the molecule and 
lead to increased attractive protein-protein interactions.  
To investigate the driving forces for fusion protein aggregation, the aggregation of the 
Fc-CTLA4 fusion protein was studied and then compared with domain conformational stability 
and overall colloidal stability at the two pH conditions discussed above. Enzymatic digests were 
attempted to obtain the individual parent domains. Biopanning experiments were also conducted 
to identify peptide ligands for the Fc-CTLA4 fusion protein for potential use in selective domain 
stabilization.  
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Figure 2-1: Model of Fc-CTLA4 fusion, courtesy of Jonas Fast and Ingemar Andre. Fc-CTLA4 
is a homodimer composed of two polypeptide chains, represented here in blue and yellow. Each 
chain has an Fc portion and a CTLA4 portion. The two chains are connected by a disulfide bond 
in the hinge region.  
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2.2 Materials and Methods 
2.2.1 Stock protein preparation: 
Fc-CTLA4 was obtained as a white, lyophilized powder with 250 mg/vial. Upon 
reconstitution with 10 mL sterile water per packaging instructions, Fc-CTLA4 is present at 25 
mg/mL in a buffer containing 50 mg/mL maltose, 1.72 mg/mL monobasic sodium phosphate and 
1.46 mg/mL sodium chloride
2
. Sodium azide at 0.01% (w/v) was added to inhibit bacterial 
growth. Following reconstitution, Fc-CTLA4 was dialyzed at 4°C into the desired experimental 
buffer using Pierce 10,000 molecular weight cut off dialysis cassettes. The experimental buffers 
include 10 mM sodium phosphate, 25 mM sodium chloride at pH 7.5 and pH 6.0, 10 mM sodium 
phosphate, 200 mM sodium chloride at pH 6.0 as well as 50 mM Tris, 25 mM MES, 25 mM 
acetic acid, 25 mM sodium chloride at pH 6.0. The two primary buffers for experimentation are 
10 mM sodium phosphate, 25 mM sodium chloride at pH 7.5 and pH 6.0, unless otherwise 
noted.  
 
2.2.2 Accelerated stability studies: 
Fc-CTLA4 at a concentration of 5 mg/mL in the desired buffer (10 mM sodium 
phosphate, 25 mM sodium chloride, 0.1 g/L sodium azide, pH 6 or pH 7.5) was aliqouoted by 
100 μL into microcentrifuge tubes. Samples were then incubated at 40°C, 30°C or room 
temperature (approximately 22°C) in order to identify conditions at which aggregation occurred 
over a reasonable time frame. Three samples per condition were removed at each time point, 
centrifuged to remove insoluble aggregates and analyzed by HPLC size exclusion 
chromatography (SEC), using a Beckman System Gold with a Waterhouse autosampler and a 
3000 SWXL Tosoh Biosciences SEC column with guard column. Unless otherwise noted, the 
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sample injection volume was 40 μL. The HPLC run time was 40 minutes at a flow rate of 0.6 
mL/min, with a 100 mM sodium phosphate, 300 mM sodium chloride mobile phase at pH 7.0. 
Data was analyzed using Bomem/GRAMS AI software. The mass of each eluting peak was 
determined using the following equation: 
 
      
               
         
 
 
where Vf is the flowrate in mL/s and ε280 is the extinction coefficient in cm
2
/mg. 
 
2.2.3 Reaction order: 
Samples with varying initial concentrations were prepared and analyzed as described in 
the accelerated stability section. The pH 7.5 samples were incubated at 40°C and the pH 6 
samples were incubated at 30°C. At pH 7.5, the initial concentrations were 2.5 mg/mL, 5 
mg/mL, 7.5 mg/mL, 10 mg/mL, 11.8 mg/mL and 13.6 mg/mL and at pH 6 the initial 
concentrations were 1 mg/mL, 5 mg/mL and 10 mg/mL. Initial concentrations are noted in the 
results.  
 
2.2.4 Fluorescence monitored unfolding: 
Fc-CTLA4 in solution at pH 6 and pH 7.5 was mixed with concentrated guanidine 
hydrochloride or urea (as indicated) to obtain increasing concentrations of denaturant. Final 
protein concentration was 0.1 mg/mL, with denaturant concentration ranging from 0-9.75 M for 
urea and 0-6 M guanidine hydrochloride. The fluorescence of the protein was measured from 
300-400 nm using an excitation wavelength of 293 nm. The scans at each concentration were 
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used to obtain the unfolding curve by plotting the center of spectral mass vs. denaturant 
concentration. This data was also used to calculate the free energy of unfolding for each 
protein/condition combination as described previously
 10, 11
.  
 
2.2.5 Thermal denaturation 
 The thermal denaturation of Fc-CTLA4 was measured by both circular dichroism (CD) 
and differential scanning calorimetry (DSC). For measurement of the Tm of the CTLA4 domain 
alone, CD was used to conserve limited materials. For the DSC experiments, samples with 
concentrations from 0.5-11 mg/mL were scanned from 5-105 °C at 1.5 atm overpressure. Scan 
rates were varied from 15-90 °C/hr. Activation energies were calculated from Tm values at 
different scan rates using the following equation
 12
: 
 
   
 
   
   
  
  
  
  
   
 
 
In the above equation, v is the scan rate, R is the gas constant, Tm is the midpoint transition 
temperature, A is a pre-exponential factor, and Ea is the activation energy.  
Far UV CD spectra was collected at 217 nm (β sheet signal) for protein samples as they 
were heated from 10 °C to 90 °C at a scan rate of 1 °C/min. Data is reported as molar ellipticity.  
 
2.2.6 Thrombin digest-  
A commercial thrombin digest kit (Thrombin Cleavage Capture Kit, Novagen, Rockland, 
MA) was used for the Fc-CTLA4 cleavage experiments. Experiments were carried out according 
to the enclosed instructions. Thrombin was provided at a stock concentration of 1 U/μL, and 
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diluted as noted. A 1:25 dilution (per kit instructions) was incubated at room temperature with 
Fc-CTLA4 for 5, 24 and 89 hours. A 1:200 thrombin dilution was incubated with Fc-CTLA4 at 
room temperature for 5 and 24 hours. The 1:25 thrombin dilution was also investigated for its 
activity at 30°C and 40°C during 12 hour incubations as well as in the presence of 25 mM 
EDTA, 1 M guanidine hydrochloride, and 25 mM EDTA/1M guanidine hydrochloride at room 
temperature. Increased thrombin concentration, above the suggested value, was also investigated, 
per Linsley et. al 1995. A final thrombin concentration of 100 U/mL was incubated with Fc-
CTLA4 under the following conditions: room temperature/96 hours, 30°C/21 hours and 40°C/21 
hours. Digestions were analyzed via SDS-PAGE. 
 
2.2.7 E. coli phage display biopanning-  
Biotinylated Fc-CTLA4 was prepared using the EZ-Link Sulfo-NHS-LC-Biotinylation 
kit (Fisher Scientific, Waltham, MA). The full OmpX E. coli phage display library was cultured 
to an OD600 of 1 in 50 mL of LB media containing 34 μg/mL chloramphenicol. 80 mL of cell 
culture were then centrifuged for 15 minutes at 3000g, supernatant removed and cells screened 
for streptavidin binding peptides. 1.25x10
9
 streptavidin coated magnetic beads (Dynabeads 
MyOne Streptavidin T1, Invitrogen, Carlsbad, CA) in PBS were added to the E. coli cells in the 
15 mL falcon tube. The cells were then incubated with the beads on an orbital shaker at 4 C for 
45 minutes, a magnet applied to the side of the tube to remove the beads and streptavidin bound 
E. coli, and the supernatant transferred to a new tube for positive section. For the positive 
selection step, the biotinylated Fc-CTLA4 was added at a concentration of 50 nM to the E. coli 
cells. The biotinylated protein and cells were then incubated on an orbital shaker for 45 minutes, 
then centrifuged and resuspended in PBS following the removal of the supernatant. 2.5x10
9
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beads were then added to the cell suspension and the incubation step repeated. Following 
incubation, the beads were washed three times by applying the magnet for 5 minutes, removing 
the supernatant and resuspending in cold PBS. After the third wash step, 1 μM biotin was added 
to remove the cells from the beads and cultured overnight in 25 mL LB media with 34 μg/mL 
chloramphenicol and 0.2% glucose. Five rounds of the magnetic cell selection were repeated to 
select for the strongest binding peptides to Fc-CTLA4. Post cell selection, cells were plated and 
individual colonies isolated for culture. Plasmids were extracted from each culture using a 
QIAGEN Plasmid Mini Prep Kit (Valencia, CA) and sequenced by Macrogen USA (Rockville, 
MD).  
 
2.3 Results 
2.3.1 Accelerated stability studies 
During accelerated stability studies, the Fc fusion, Fc-CTLA4, exhibited markedly 
different aggregation rates with only a small shift in pH. An increase of two orders of magnitude 
in the aggregation rate was observed when changing the solution pH from pH 7.5 to pH 6. At pH 
7.5 and 40 °C, the rate of monomer loss was 6 μg*mL-1*h-1, which corresponds to an apparent 
first order reaction rate constant of 0.0012 ± 0.0002 h
-1
. At pH 6 the observed aggregation 
rate/apparent first order rate constant increased to 800 μg*mL-1*h-1 and 0.16 ± 0.012 h-1, 
respectively. With these differences in reaction rates, it took 15 days of incubation at pH 7.5 to 
see the same amount of monomer loss that was observed after 5 hours at pH 6 (Figure 2-2). 
There were further differences in the type of aggregate species present as well. All of the 
aggregates at pH 6.0 appeared to be soluble, with no detectable monomer loss by SEC. There 
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were insoluble aggregates present at pH 7.5 as a pellet was visible after centrifugation of the 
sample and SEC peak area was not conserved.  
Increasing the concentration of sodium chloride to 200 mM at pH 6 resulted in only a 
slight decrease in aggregation, with the apparent first order reaction rate constant being reduced 
to 0.1 ± 0.03 h
-1
. Aggregation studies in the Tris/MES/acetic acid buffer system at pH 6 
exhibited similar aggregation compared to the other buffers at that pH with an apparent first 
order rate constant of 0.08 ± 0.01 h
-1
.   
The change in pH also lead to differences in reaction order, indicating a different 
mechanism controls aggregation at the two pH values. At pH 6 the apparent reaction order is 
between 1
st
 and 2
nd
 order and at pH 7.5 it is higher than 2
nd
 order with a possible concentration 
dependence. 
 
2.3.2 Conformational stability 
Chemical denaturation of Fc-CTLA4 by urea shows the presence of two unfolding 
transitions in Figure 2-3. The first unfolding transition is shifted to lower concentrations of 
denaturant at pH 6 as compared to pH 7.5, indicating that the change in pH is reducing the 
conformational stability of this domain. This is supported by the change in the free energy of 
unfolding for the transitions. The free energy of unfolding for the first transition was 14.5 ± 1.3 
kJ/mol at pH 7.5 and 6.8 ± 1.3 kJ/mol at pH 6 in phosphate buffer. The second unfolding 
transition is not affected by the change in pH. 
The buffer species has no impact on the unfolding transitions at pH 6, demonstrated by 
the overlapping curves in Figure 2-3 and the fact that the ΔGunf for the first transition in the 
Tris/MES/acetic acid buffer was 6.0 kJ/mol, which is very close to the ΔGunf in the phosphate 
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Figure 2-2: Size exclusion chromatograms of 40 C incubated samples at pH 7.5 (Panel A) and 
pH 6.0 (Panel B). Samples incubated one day (dotted) and 15 days (dashed) are compared to the 
stock protein (solid line) at pH 7.5 in Panel A and samples incubated 2.5 hours (dotted) and 5 
hours (dashed) are compared to the stock protein (solid line) at pH 6.0 in Panel B.  
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Figure 2-3: A) Fc-CTLA4 chemical denaturation at pH 6 () and pH 7.5 () in 10 mM sodium 
phosphate, 10 mM NaCl buffer. B) Fc-CTLA 4 chemical denaturation at pH 6 in either 10 mM 
sodium phosphate, 25 mM NaCl () or 50 mM Tris, 25 mM MES, 25 mM acetic acid, 25 mM 
NaCl (). Note that the first transition has an earlier onset at pH 6 versus pH 7.5. No difference 
is observed at pH 6 as a function of buffer species.  
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buffer system. 
 Thermal denaturation of the Fc-CTLA4 fusion protein as measured by far UV CD 
exhibits two unfolding transitions. The CTLA4 domain alone undergoes one unfolding transition 
which overlaps with the first transition of the intact fusion (Figure 2-4). When measured by 
DSC, the fusion also exhibits two distinct unfolding transitions separated by 30 °C. The 
activation energy for the first transition was calculated to be 297 ± 13 kJ/mol at pH 6 and 361 ± 
19 kJ/mol at pH 7.5. The activation energy for the second transition was not affected by the shift 
in pH (391 ± 14 kJ/mol at pH 6 and 391 ± 20 kJ/mol at pH 7.5).  
 
2.3.3 Colloidal Stability 
The second osmotic virial coefficients (B22) were calculated from static light scattering 
data and can be seen in Table 2-1. As mentioned previously, the B22 is a measure of protein-
protein interactions in solution. In the sodium phosphate buffer, at both pH 7.5 and pH 6, the net 
interaction is attractive. Switching to a Tris/MES/acetic acid buffer system at pH 6 results in 
repulsive protein-protein interactions. Table 2-1 also includes the relative aggregation rate for 
each buffer condition. The aggregation rate at pH 7.5 is low, compared to the aggregation in both 
pH 6 buffers which is relatively high.  
 
2.3.4 Enzymatic digests 
In order to compare the stability of the domains with the overall protein stability, enzymatic 
digestion of Fc-CTLA 4 was attempted as a way to separate the domains. The presumed 
sequence of Fc-CTLA 4 includes a thrombin digest site in the hinge region
 8, 13
. One 50 
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Figure 2-4: A Far UV CD thermal melt followed at 217 nm (β sheet signal) shows two 
transitions for the complete fusion protein, whereas CTLA 4 undergoes one transition that 
coincides with the first transition of Fc-CTLA 4.  
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Buffer System pH  2
nd
 Virial 
Coefficient  
x 10
4
  (mL*mol*g
-2
) 
Net interaction 
 
Relative 
Aggregation 
Rate 
Sodium 
phosphate 
7.5 -6.0 ± 1.9  Attractive Low 
Sodium 
phosphate 
6 -6.5 ± 3.7 Attractive High 
Tris/MES/acetic 
acid 
6 6.55  Repulsive High 
 
Table 2-1: Comparison of colloidal stability and aggregation rate based on pH and buffer 
system. B22 values were obtained by Jonas Fast, PhD.  
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
kDa portion (CTLA4 domain) and two 22.5 kDa portions (Fc domains) are expected if the 
protein was cleaved in the hinge region. However, the digestion results show one 75 kDa band 
and one 50 kDa band by SDS-PAGE. This indicates that the protein is not completely cleaved 
between the Fc and CTLA-4 portions. Figure 2-5 is a photograph of the SDS-PAGE gel showing 
the size of the fragments obtained from the digest. 
 
2.3.5 E. coli Phage Display Biopanning-  
Seventeen potential binding peptides were identified and are listed in Table 2-2 along 
with their theoretical pI values. Theoretical pI values for the peptides were calculated using 
SwisProt.  
 
2.4 Discussion 
Given that the two domains of the Fc-CTLA4 fusions should be oppositely charged at pH 6 and 
less so at pH 7.5, one might expect that protein-protein interactions and colloidal stability play a 
large role in the aggregation of this protein. However, since relatively high aggregation rates 
were observed for both buffer systems at pH 6 where the net interactions were either attractive or 
repulsive depending on the buffer, and low aggregation rates were observed at pH 7.5 where the 
net interaction is attractive, it is apparent that B22 does not correlate with aggregation rate. Thus 
colloidal stability is most likely not driving the aggregation of this protein.  
Although no differences in colloidal stability between the phosphate buffer conditions at 
pH 7.5 and pH 6 were observed, there were large changes in conformational stability. The shift 
from pH 7.5 to pH 6 decreased the free energy of unfolding (ΔGunf) of the first transition by over 
half. This pH shift had no effect on the second unfolding transition of the Fc-CTLA4 fusion. 
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Figure 2-5: SDS-PAGE of thrombin digest samples. The upper oval is highlighting the 75 kDa 
band and the lower oval is highlighting the 50 kDa band. Stock Fc-CTLA4 is included in the first 
lane, directly to the left of the molecular weight ladder in the second land. Stock thrombin was 
included in the far right land for comparison with the digested samples.  
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Peptide Sequence Theoretical pI* 
G N K M W R R 12.01 
N M P Q R R T 12.00 
R K S Y W R Q 11.00 
L R G P A N K 11.00 
Y K N N G R R 11.00 
V C R R G F Q 10.35 
G R Q C T R L 10.35 
T I M N R W S   9.41 
E V N K R W I 8.85 
V Q K K E I S 8.56 
E A T Y K E R 6.24 
W V A S E W K 6.00 
W M S G M D R 5.84 
F K L A D T F 5.84 
N V T I N F X 5.52 
R I E E T T Q 4.53 
L N G V D I S 3.80 
 
Table 2-2: Peptide sequences identified by phage display that potentially bind Fc-CTLA4 and 
the theoretical pI values corresponding to each peptide sequence. 
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Two distinct unfolding transitions were also present when measured by DSC, separated by 
approximately 30 °C.  
Since there are no tryptophan residues in the CTLA4 domain
 8
, the unfolding of said 
domain should not be detectable by intrinsic fluorescence. Thus the two transitions visible during 
chaotrope denaturation likely correspond to the CH2 and CH3 regions of the Fc domain. 
However, if all three domains were unfolding independently, one would expect to see three 
transitions during thermal denaturation. This is not the case. Only two thermal transitions are 
observed. When measured alone, CTLA4 at pH 7.5 show a single transition with Tm = 58 °C 
which is close to the first transition of the intact fusion protein. This leads to the conclusion that 
the CTLA4 and CH2 domains are the least conformationally stable with overlapping unfolding 
transitions.  
 Solution conditions with an increased aggregation rate corresponded to those where the 
conformational stability of the CTLA4 and CH2 domains was reduced. The shift in pH also 
reduced the activation energy for aggregation.  
 The thrombin digest did not successfully cleave the fusion protein into the separate intact 
Fc and CTLA4 domains. The most likely explanation of the results is that the two Fc portions are 
cleaved off individually, and that the 75 kDa band seen in the gel still has one Fc portion while 
the approximately 50 kDa band is only the CTLA4 domain. An additional complication is that 
the thrombin stock produces a band around 20 kDa which may mask Fc fragments. MALDI-TOF 
MS yielded inconclusive results on the sizes of the Fc-CTLA4 fragments. Furthermore, digestion 
only occurred in samples where the thrombin concentration was increased to 100 U/mL and 
digestion yields were too low to provide sufficient materials for further experiments. The 
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inability to separate the fusion domains for further experimentation limits the utility of the Fc-
CTLA4 fusion as a model protein for further studies.  
 The E. coli phage display biopanning did not identify a strong candidate for a potential 
peptide ligand for Fc-CTLA4. There was no strong consensus between the seventeen sequences 
identified, although 40% of the peptides identified had a theoretical pI above 10. Additionally, 
since the entire Fc-CTLA4 fusion protein was used for the biopanning, the peptides may not bind 
the CTLA4 domain as desired for selective stabilization of the least conformationally stable 
domain. Another concern is that the CTLA4 domain is unlikely to be the conserved domain. 
Thus any peptide identified to stabilize CTLA4 is not expected to be useful beyond this fusion 
construct.   
 
2.5 Conclusions 
Fc-CTLA4 is highly sensitive to changes in pH. Maximizing domain conformational 
stability results in the most stable formulation for this fusion. However, the inability of 
separating the domains and the lack of domain selective stabilizing candidates makes this a 
difficult system to study and leaves several questions unanswered. Furthermore, the Fc domain is 
likely to be the conserved domain in future fusion protein products and thus work aimed at 
increasing the conformational stability of the CTLA4 domain may not be useful beyond this 
case.  
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CHAPTER 3 
 
CHOOSING APPROPRIATE ACCELERATED STABILITY STUDIES TO RANK THE 
STABILITY OF POTENTIAL PROTEIN FORMULATIONS 
 
 
3.1 Introduction 
 
Shelf-life requirements of therapeutic protein products necessitate aggregate levels in the 
very low percentages at the end of the storage period
 1
. Under real storage conditions, most 
commonly used analytical techniques are unable to quantify the low aggregation rates implied by 
this requirement within a timeframe that is reasonable for development of formulations. Thus, in 
order to screen for formulation conditions most likely to provide acceptable long-term storage 
stability, accelerated degradation studies are used to screen formulations. For example, stability 
of proteins within formulations is often assessed by subjecting test formulations to elevated 
temperatures and measuring (e.g., using microcalorimetry or various optical spectroscopies) the 
“melting” temperature Tm at the midpoint of unfolding. Although interpretations of Tm are more 
complicated with multidomain proteins that may exhibit separate Tm values for each domain, 
formulations that result in lower Tm values generally correlate with increases in aggregation rates 
at temperatures less than Tm
 2
. Models have also been developed to better predict low-
temperature behavior from the elevated-temperature stability studies, including incubation 
studies
 3, 4
. The recent work of Brummit, et al., has very nicely shown the predictive ability of 
high-temperature scans for estimating the aggregation rates observed in liquid formulations 
under lower-temperature storage conditions
 4
. The temperature-scanning monomer loss approach 
predicted the observed rate coefficients for shelf-lives ranging over orders of magnitude
 4
. This 
approach was also able to capture both the unfolding and association aspects of aggregation
 4
. 
However, aggregation is a concern during the entire product life-cycle, including manufacturing 
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and transport
 5, 6, 7
, and accelerated stability studies at elevated temperature may still not capture 
all of the aggregation mechanisms involved, especially those involving interfaces. Thus there is a 
benefit to understanding how accelerated stability studies at elevated temperature compare with 
accelerated stability studies involving other stresses such as agitation or freeze/thawing.  
It is very common for proteins to be exposed to air/water and water/ice interfaces, as well 
as freeze concentration during manufacture and shipping. Pumping or stirring of protein 
solutions during the manufacturing process
 5
 results in greater exposure of proteins to air/water 
interfaces.  Likewise, vibrations during shipping may increase air-water interfacial surface areas, 
and pump cavitation can increase exposure of proteins to air/water interfaces
 6, 8
. During the 
manufacturing process, protein may be frozen as bulk drug substance to meet the demands of the 
campaign schedule
 9
. Additionally, products which are designed for in home administration may 
experience inadvertent freezing/thawing during at-home storage
 10
. Not only does freezing create 
a water/ice interface which can induce protein damage
 11
, but freeze concentration of the protein 
in the liquid phase can also crowd molecules together and increase propensity for association and 
aggregation
 12
. 
The type and duration of stress are important factors in the formation of protein 
aggregates. Previous studies have shown that different stresses can lead to differences in the 
amount and type of aggregates produced. Freeze-thaw cycling has been shown to produce 
different protein aggregate types and amounts than are produced by heating,
 13, 14
 and to produce 
fewer particles than agitation
 14
. Subcutaneously injected protein aggregates produced by freeze-
thawing elicited different immune responses from those formed by agitation
 15
.   Stirring has 
been shown to be a more harsh agitation stress than shaking
 16
. Even when stirring is considered 
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alone, the orientation of the stirring mechanism itself (e.g. top versus bottom) can lead to 
differences in aggregate formation
 17
. 
Further complicating analysis of the aggregation is that protein aggregates may be found 
at low concentration and span a broad range of sizes, making their quantitation problematic.  
Size exclusion chromatography (SEC) can provide accurate quantification of monomer and 
lower-order aggregates (e.g., dimers, trimers) but may miss subvisible particles that are filtered 
out by the column resin
 18
. Characterizing these subvisible particles is desirable since they have 
been implicated in potentially causing adverse immune responses
 19, 20, 21
. Utilizing flow imaging 
in conjunction with SEC can help provide a more complete picture of product behavior upon 
exposure to process changes/stresses
 22
.  
Here we compare the previously determined mechanism responsible for thermally-
induced aggregation of abatacept, an Fc-CTLA4 fusion protein, to the aggregation induced by 
agitation or freeze/thawing in solutions at both pH 7.5 and pH 6.0. Previously, conformational 
instability was determined to be the main factor leading to aggregation of abatacept during 
accelerated stability studies conducted at elevated temperatures
 23
.  At elevated temperatures, the 
domains of abatacept sequentially unfold. The CTLA4 domain and the CH2 region of the Fc 
domain unfold during the first transition, and the CH3 region of the Fc domain unfolds during the 
second transition. Abatacept was found to be less conformationally stable (i.e., the free energy of 
unfolding for the first unfolding transition was approximately 8.5 kJ/mol lower) and more 
aggregation-prone in solutions at pH 6.0 relative to solutions at pH 7.5
 23
. Given that several 
accelerated methods often are used to predict long term storage behavior, it is useful to 
understand how the choice of accelerated method influences the ranking of formulation 
stabilities. Here, freeze/thaw and agitation studies were used to evaluate the stability of abatacept 
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formulations to stresses beyond elevated temperature and compare how differences in 
conformational stabilities between formulations influence the aggregation of abatacept.  
 
3.2 Materials and Methods 
3.2.1 Stock Protein Preparation  
Abatacept, an Fc-CTLA4 fusion protein, was obtained as a lyophilized white powder 
(marketed as Orencia®, Bristol Myers Squibb, New York, New York). After reconstitution 
according to package instructions, abatacept was dialyzed into the experimental buffer: 50 mM 
Tris, 25 mM MES, 25 mM acetic acid and 25 mM NaCl (pH 6.0 or pH 7.5) as noted. All buffers 
contained 0.01% w/v sodium azide to inhibit microbial growth and were filtered with a 0.22 μm 
nitrocellulose filter (Millipore, Cork, Ireland) prior to dialysis. 
 
3.2.2 Agitated sample preparation 
Stock protein was diluted to a final concentration of 1 mg/mL. 400 μL aliquots were 
placed in 0.6 mL polypropylene microcentrifuge tubes (Fisher brand). The centrifuge tubes were 
secured horizontally on an orbital titer plate shaker (Lab-Line Instruments, Inc., Melrose Park, 
IL). Samples were agitated for 1, 3 or 6 hours at shaker intensity setting 5 or 10.  
 
3.2.3 Freeze thaw sample preparation 
400 μL of solutions containing abatacept at a concentration of 1 mg/mL were aliquoted 
into 0.6 mL polypropylene microcentrifuge tubes. One of two freeze/thaw protocols was used. 
Samples were either frozen in liquid nitrogen for 1 minute and then thawed for five minutes in a 
water bath at 23.5 °C (fast protocol) or frozen at -20 °C for 30 minutes and thawed at 4 °C on a 
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refrigerator shelf for two hours (slow protocol). The liquid nitrogen freezing protocol was 
repeated for a total of 5 or 20 cycles and the -20 °C freezing protocol was repeated for a total of 5 
cycles.  
 
3.2.4 Stressed sample storage  
After application of the respective stress, freeze thaw- or agitation-stressed samples were 
stored in the original microcentrifuge tubes for 24 hours at 4 °C before analysis to observe if any 
changes in aggregate profile occurred. Samples were stored quiescently in a vertical orientation.  
 
3.2.5 Size exclusion chromatography (SEC) 
Prior to SEC analysis, samples were centrifuged for 5 minutes to remove larger 
aggregates. Samples were then injected onto a Tosoh Bioscience 3000swxl gel column 
(Montgomeryville, PA) using a Waters 717plus autosampler (Waters Technologies Corporation, 
Milford, MA). A Beckman System Gold with a 166 detector (Beckman Coulter, Brea, CA) was 
used to control the flow rate and measure the absorbance of the eluate. The mobile phase 
consisted of 100 mM sodium phosphate, 200 mM sodium chloride at pH 7.0 and the flowrate 
was 0.6 mL/min. The mass of protein in the peak of interest was calculated using Equation 1: 
 
(1)       
              
         
 
where Vf is the flowrate in mL/s and ε280 is the extinction coefficient of the protein in cm
2
/mg. 
 
3.2.6 Micro Flow Imaging (MFI) Analysis  
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The Brightwell Dynamic Particle Analyzer 4100 particle imaging system (Ottawa, 
Ontario, Canada) was used to collect particle counts for the stressed and unstressed samples. The 
instrument was operated in normal mode with low magnification and a vertical cell orientation. 
For each sample, 0.15 mL were dispensed prior to analysis in order to minimize dead-volume 
effects. The cell was flushed with filtered water between protein samples until particle counts 
returned to the original pre-sample levels. Samples were not centrifuged prior to analysis by 
MFI. The total mass of aggregates present in each sample was estimated as previously described
 
22
. Briefly, binned particle counts reported from MFI analysis were converted to particle mass 
per bin by assuming that each size bin represented spherical particles with a diameter equal to the 
bin midpoint. The volume of particles in each size bin was calculated, and then converted to 
mass concentration (Mp) by multiplying by an effective protein density using Equation 2: 
 
(2)                
 
where V is particle volume, φ is fraction of protein within particle, ρ is the protein density, and ni 
is particle population density in size bin i. For these estimations, a protein fraction within the 
particles of ¾ and a protein density of 1.43 g/mL were used
 22
. 
 
3.2.7 Conformational stability of abatacept at 4 °C  
Conformational stability of abatacept at 4 °C was determined using the chaotrope 
perturbation method described previously
 24
 to calculate the free energies of unfolding. Abatacept 
samples at a concentration of 0.1 mg/mL were incubated overnight in guanidine hydrochloride 
(0-6 M) prior to fluorescence measurement. To measure intrinsic fluorescence, the samples were 
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excited by light at a wavelength of 293 nm and the resulting emission spectra from 300-400 nm 
were recorded using an Aminco Bowman Series 2 fluorescence spectrophotometer (SLM 
Aminco, Urbana, Illinois). The center of spectral mass (CSM) of each emission spectrum was 
calculated using Equation 3: 
(3)      
     
   
 
 
In Equation 3, Fi is the fluorescence intensity at a given wavenumber, vi. Plots of CSM values 
versus chaotrope concentration were then fit to a two state unfolding model using a linear least-
squares fit to Equation 4 to calculate the free energies of unfolding (ΔGNU)
 25
. Equation 5 
represents the linear approximation for ΔGNU for chaotrope-induced denaturation
 25
.  
 
(4)     
                             
     
  
 
       
     
  
 
 
 
(5)                         
 
In Equation 4, kN and kU are the slopes of the baselines of the native and unfolding states 
respectively, bN and bU are the intercepts of these baselines, Y0 is the center of spectral mass 
value, T is temperature, and R is the molar gas constant. In Equation 5, [D] is the concentration 
of the chaotrope and m represents dΔGNU/d[D] (i.e., the sensitivity of ΔGNU to chaotrope 
concentration). ΔGNU(D) is the free energy of the unfolding with chaotrope present and 
ΔGNU(H20) is the free energy of unfolding at a zero chaotrope concentration.  
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3.2.8 Colloidal stability of abatacept at 4 °C 
 Zeta potential values were calculated at 4 °C to serve as an indicator of colloidal stability. 
The Malvern Zetasizer Nano ZS (Worcestershire, United Kingdom) was used to measure 
electrophoretic mobility of the protein samples. These data were converted to zeta potential 
values using the Smoluchoski approximation to Henry’s equation (Equation 6) 26.  
(6)      
     
  
 
In Equation 6, μe is the elecrophoretic mobility, η is the solution viscosity,   is the dielectric 
constant, ζ is the zeta potential and ks equals 1.5 in the Smoluchoski approximation. Protein 
samples at 4 °C and a concentration of 1 mg/mL were placed in disposable folded capillary cells 
(Malvern Instruments Ltd, Worcestershire, United Kingdom). Three separate samples were 
measured for each solution condition and the reported values represent the average ± the 
standard deviation.   
 
3.3 Results 
3.3.1 Thermal stability of abatacept 
For ease of comparison, we first summarize the major experimental result of a previously 
reported study on the stability of abatacept against aggregation accelerated by incubation at 
elevated temperatures
 23
. In these earlier studies, a two order of magnitude increase in the 
aggregation rates at pH 6.0 relative to pH 7.5 conditions was seen during accelerated stability 
studies at 40 °C 23.This increase in aggregation correlated with the decreased activation energy 
(measured by scanning calorimetry) and decreased free energy of unfolding for the first 
structural transition at pH 6.0 versus pH 7.5
 23
. The first structural transition corresponds to the 
unfolding of the CTLA4 domain and the CH2 region of the Fc domain
 23
. 
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3.3.2 Conformational stability of abatacept at 4 °C 
 ΔGNU values for abatacept measured at 4 °C are lower in solutions at pH 6.0 than values 
measured in solutions at pH 7.5 (Table 3-1). Lower conformational stability at pH 6.0 compared 
to pH 7.5 was also observed previously at 25 °C (Table 3-1) 23. However, although the relative 
order of stabilities with respect to pH remains the same between the two solution conditions at 
either temperature (i.e., the protein is less conformationally stable at pH 6.0 than at pH 7.5), the 
conformational stability was increased at 4 °C compared to 25 °C (Table 3-1).  
 
3.3.3 Colloidal stability of abatacept at 4 °C 
 Although colloidal instability was determined not to be a major contributor to the 
aggregation of abatacept at elevated temperature
 23
, it still may be an important factor in the 
freeze thaw studies here. Since pKa values are a function of temperature
 27
, the potential exists 
for protein-protein electrostatic interactions to vary between 4 °C and 25 °C because the charge 
state of the molecule may change. However, that was not seen to be the case. Zeta potential 
values are the same at 4 °C and 25 °C (Table 3-1), indicating that there is not a large temperature 
dependence on the electrostatic contributions to colloidal stability of abatacept in the range 2-25 
°C.  
 
3.3.4 Freeze/thaw induced aggregation 
No significant changes in monomer concentration were detected by SEC for samples 
stressed by either freeze/thaw protocol. This observation held in formulations at both pH 6.0 and 
7.5. When the freeze-thaw cycled samples were stored at 4 °C for 24 hours and then analyzed by  
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pH ΔGNU (kJ/mol) at 
4 °C 
ΔGNU (kJ/mol) at 
25 °C* 
Zeta potential (mV) 
at 4 °C 
Zeta potential (mV) at 
25 °C 
6.0 12.1 ± 1.4 7.1 ± 0.6 -2.7 ± 1.3 -2.7 ± 1.4 
7.5 21.4 ± 2.3 15.6 ± 1.2  -1.3 ± 0.5 -2.9 ± 2.8 
 
Table 3-1: Conformational and colloidal stability of abatacept as a function of temperature at pH 
6.0 and pH 7.5. Values represent the average of three samples ± the standard deviation. *ΔGNU 
values for abatacept at 25 C are from Fast et al. 2009.  
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SEC, no changes were observed. There were no soluble high molecular weight aggregates 
detected by SEC at either pH condition. 
Although no high molecular weight  aggregates could be detected by SEC, MFI analysis 
showed increased numbers of particles in solution for samples subjected to freeze-thaw cycling. 
After five slow freeze thaw cycles, average particle counts increased by a larger degree at pH 6.0 
than at pH 7.5 in most of the size ranges analyzed, with the exception of particles larger than 25 
μm (Figure 3-1). After five freeze thaw cycles, the average particle concentration in the 2-5 μm 
range increased by 5.2x at pH 6.0 and by 1.6x at pH 7.5. Particles per mL in the 5-10 μm range 
increased by 10.1x at pH 6.0 and 1.2x at pH 7.5. Particles per mL in the 10-25 μm size range 
increased by 6.7x at pH 6.0,and doubled at pH 7.5. The concentration of particles larger than 25 
μm increased by only 10% at pH 6.0 and 50% at pH 7.5.  
Samples stressed by application of 20 cycles of the fast freeze/thaw protocol contained 
large numbers of air bubbles, complicating the analysis by MFI. However, after only 5 fast 
freeze/thaw cycles, an increase in particles was observed at both pH conditions, with a larger 
number of particles detected in the pH 6.0 samples (Figure 3-2). After 24 hours of storage the 
samples stressed by 5 fast freeze thaw cycles exhibited greater differences in particle 
concentrations between solutions at the two pH values compared to unstressed samples. The 
concentration of particles in each size range decreased significantly after 24 hours storage at pH 
7.5, with over a 50% loss of particles upon storage for all size ranges. For samples formulated at 
pH 6.0, this decrease in particle numbers upon storage was not seen.  
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Figure 3-1: Slow freeze thaw stressed samples (5x) showing particle concentrations for each 
equivalent spherical diameter size range. Panel A represents the 2-5 μm size range, panel B the 
5-10 μm range, panel C the 10-25 μm range and panel D represents particles 25 μm and above. 
Samples include stock protein (black) and protein after 5 freeze-thaw cycles (gray). In panels A-
C (i.e., particles up to 25 μm), freeze thaw stress increases particle concentrations in solutions at 
pH 6.0 but not in solutions at pH 7.5. The concentration of particles greater than 25 μm did not 
increase after freeze thawing at either pH condition; however, the concentration of particles at 
pH 6.0 was high initially.  
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Figure 3-2: Fast freeze thaw stressed samples (5x) showing particle concentrations for the 2-5 
μm size range (Panel A), the 5-10 μm size range (Panel B), the 10-25 μm size range (Panel C) 
and the greater than 25 μm size range (Panel D). Samples include stock protein (black), protein 
after 5 freeze-thaw cycles (light gray) and the freeze thaw stressed protein after 24 hours storage 
(medium gray).  Although particle concentrations increased in all size ranges after 5 fast freeze 
thaw cycles for both pH conditions, the particle concentrations decreased much more at pH 7.5 
than at pH 6.0 after 24 hours of storage.  
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3.3.5 Agitation induced aggregation 
Agitated samples exhibited significant amounts of monomer loss as measured by SEC 
after only one hour of agitation at an orbital shaker setting of level 10, as seen in Figure 3-3. 
Despite the similarities in monomer loss between the two pH conditions after only one hour 
agitation, larger differences in aggregation were detected at later time points. Soluble higher 
molecular weight species were also detected by SEC at pH 6, but not at pH 7.5. In the samples 
formulated at pH 6.0 where higher molecular weight species were detected, there was still 
incomplete recovery of the initial mass. After 6 hours of agitation at pH 6.0, approximately 87.8 
± 3.0% of the initial mass was recovered. No changes in monomer levels were seen after the 
stressed samples were stored for 24 hours at 4 °C (data not shown). 
When MFI was used to analyze samples agitated for three hours, it was found that the pH 
6.0 formulation did not show as great of an increase in particle number as that seen in the pH 7.5 
formulation, even though initial particle numbers were comparable. For example, the amount of 
particles per mL in the 2-5 μm size range increased by only 5x at pH 6.0 compared to an 11x 
increase at pH 7.5. However, the standard deviation for the particle count was very large, with 
the particle number per mL differing by an order of magnitude over the three agitated samples. 
The amount of particles detected in solutions at either pH did not change significantly after 24 
hours of storage (Figure 3-4). 
The mass of protein present in the particles was also estimated from MFI measurements 
for samples agitated three hours at either pH 6.0 or pH 7.5, and compared with the monomer loss 
detected by SEC. The results of these calculations indicated there were 8.4 ± 5.5 μg/mL of 
protein present in the particles detectable by MFI at pH 6.0. However, the amount of monomer 
loss detected by SEC at pH 6.0 was approximately 160 ± 20 μg /mL. The mass of the high  
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Figure 3-3: Percent of initial monomer remaining after agitation for 1, 3 or 6 hours. Monomer 
loss increases the longer samples are exposed to agitation. As the time over which samples were 
exposed to agitation increased, samples formulated at pH 6.0 (white bars) exhibited greater 
amounts of monomer loss than those formulated at pH 7.5 (gray bars).  
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Figure 3-4: Agitation stressed samples showing particle concentrations for the 2-5 μm size range 
(Panel A), the 5-10 μm size range (Panel B), the 10-25 μm size range (Panel C) and the greater 
than 25 μm size range (Panel D). Samples include stock protein (black), samples agitated for 3 
hours (light gray) and the 3 hour agitated samples stored for 24 hours (medium gray). In 
solutions at pH 7.5, particle concentrations increase for all size ranges after three hours of 
agitation. For samples in solution conditions at pH 6.0, the increase in particle count is lower 
than at pH 7.5. Significant decreases in particle concentrations are not observed in either solution 
condition after 24 hours storage.  
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molecular weight species (HMWS) detected accounts for 40 μg/mL of the initial monomer lost, 
but there is still incomplete mass recovery in samples at pH 6.0. At pH 7.5, 86 ± 110 μg/mL of 
protein was present in the particles, which is similar to the 80 ± 3 μg/mL monomer loss detected 
by SEC. Furthermore, no HMWS were detected by SEC in the pH 7.5 samples.    
 
3.4 Discussion 
Although calorimetry is frequently used as a formulation screening tool, the relatively 
high temperatures required for calorimetric assessment of conformational stability raises the 
question as to whether the results are relevant for predicting aggregation induced by stresses 
other than temperature. Differences in aggregation mechanisms might be expected, because 
aggregation during thermal stability studies occurs in the bulk, whereas aggregation during 
freeze/thaw cycling or agitation is likely influenced by conformational stability at air-water or 
ice-water interfaces.  For these routes of damage, the propensity of a protein to adsorb to an 
interface and its stability at that interface would be important and not necessarily captured by 
thermal studies, as thermal stability of proteins has been shown to decrease upon surface 
adsorption
 28
. For example, recombinant human growth hormone aggregates rapidly at air-water 
interfaces in spite of its relatively high thermal stability (Tm approximately 80 C at pH 6.0)
 29, 30
.  
However, for abatacept, the use of elevated temperatures to accelerate degradation 
23
  
appears to be relevant to aggregation induced by freeze/thaw or agitation interfacial stresses. At 
elevated temperature, greatly increased aggregation was observed at pH 6.0 compared to pH 7.5. 
Calorimetric analysis showed that activation energies for unfolding decreased at the lower pH 
condition, and the free energy of unfolding was reduced.  In the current study, during agitation 
and freeze/thaw studies, decreased monomer loss and reduced particle formation rates were 
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observed in solutions at pH 7.5 compared to those at pH 6.0. Since the rate limiting step for 
aggregation during thermally-accelerated stability studies was related to abatacept 
conformational stability
 23
, it is not surprising that the thermal screening results correlate with 
what was seen here; interfaces faces might serve only to further destabilize the conformation of 
abatacept. It is possible the results from accelerated stability studies based on thermal stress, 
agitation, and freeze-thawing would not correlate as well in cases where association is the rate 
limiting step for aggregation, since conformational instability would not be playing as large a 
role in the aggregation pathway.  
 Capturing the interfacial component in accelerated stability studies is important because 
the extent of damage caused by the agitation and freeze/thaw stresses appears to be a function 
not only of the conformational stability, but also a function of the fluidity of the interface. 
Previous work studying the agitation-induced aggregation of abatacept in syringes showed 
increased particle counts when silicone oil contributed a fluid-fluid interface, but no increases in 
particle counts for agitation in syringes without silicone oil at pH 7.2 
31
. In this current study, 
agitation exposed abatacept to large amounts of dynamic air/water interfacial area. At this fluid-
fluid interface, large amount of aggregates were formed. The amount of monomer loss at pH 7.5 
was less than at pH 6 and correlates with the increased conformational stability of the protein at 
pH 7.5. Unlike the results seen in agitation studies, freeze/thaw cycling did not result in large 
amounts of aggregation. As no significant difference in colloidal stability was detected between 
4 °C and 25 °C, it is possible the increased conformational stability at 4 °C is responsible for the 
decreased amounts of monomer loss observed. However, the fluidity of the interface is likely an 
important factor as well, with the solid/liquid interface of ice/water being less fluid than the 
air/water interface. Increased turnover of a fluid interface would return unfolded or 
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conformationally perturbed proteins at the surface to the bulk formulation, accounting for the 
increased aggregation seen in the agitation studies. This observation fits with the results of a 
previous study of abatacept aggregation in the presence of silicone oil
 31
. Abatacept aggregation 
increased with the addition of silicone oil and this fluid/fluid interface (i.e., buffer/silicone oil) 
appears to be more damaging than the solid/fluid interface of the glass/buffer alone
 31
. Although 
shear by itself typically is not sufficient to damage therapeutic proteins
 8, 32, 33
, similar effects of 
air/water interfacial turnover have also been seen in the aggregation of recombinant human 
growth hormone (rhGH)
 34
. rhGH exposed to shear in the absence of an air/water interface did 
not aggregate significantly, but aggregated to a large degree when the air/water interface was 
present. Aggregation of rhGH in the presence of an air/water interface increased with increasing 
shear rate, likely due to greater interfacial turnover. The observed aggregation rate was first order 
with respect to protein concentration, indicating that conformational stability plays a large role in 
the aggregation of rhGH induced by interfacial turnover
 34
.  
The differences in reversibility of particles formed by freeze thawing at pH 7.5 versus 
those formed by agitation are likely the result of the milder freeze thaw stress compared to 
air/water interfacial turnover during agitation and the increased conformational stability of the 
protein at pH 7.5. If the protein is less structurally perturbed, the particles formed will then be 
less stable compared to particles formed from a more unfolded protein structure.  
Although MFI was useful in examining differences in formulation conditions where 
aggregation was undetectable by SEC, it bears mention that there were still limitations with this 
method. Unlike previously reported studies
 22
, the amount of protein in particles detected by MFI 
did not agree with the monomer loss as detected by SEC in all cases. After a three hour agitation 
of samples at pH 7.5, where no higher molecular weight aggregates were detected by SEC, there 
62 
 
is close agreement between the MFI and SEC results (86 ± 110 μg/mL of protein in particles 
versus 80 ± 3 μg/mL of monomer lost). However, at pH 6.0, there is not a good agreement 
between the monomer lost and the amount of protein in the particles after agitation. The 160 ± 20 
μg /mL loss of monomeric abatacept at pH 6.0 was greater than that observed at pH 7.5 (80 ± 3 
μg/mL) after three hours of agitation, but only 8.4 ± 5.5 μg/mL of protein in particles were 
detected. The mass of the soluble aggregates detected by SEC is not enough to account for the 
difference. Since there is still a gap in particle detection in the 0.1-1 μm size range, it is possible 
that if these particles could be included that the particle mass balance would accurately reflect 
the monomer loss at pH 6.0 and give a more complete picture of the aggregation.  
 
3.5 Conclusions 
Thermal stability studies were predictive of the relative stabilities of formulations 
subjected to freeze/thaw and agitation stresses. Conformational stability of this protein controlled 
the rate limiting step during aggregation at elevated temperature, and damage as a result of 
agitation or freeze/thaw cycling also was increased in formulations where the protein had a lower 
conformational stability.. While all three methods provided the same relative ranking of 
formulation stability, the differences in damage due to interfacial fluidity suggest careful 
selection of an appropriate accelerated stability study is still important.  
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CHAPTER 4 
 
SELECTIVE DOMAIN STABILIZATION AS A STRATEGY TO REDUCE FUSION 
PROTEIN AGGREGATION 
 
(This work has been submitted as Amanda A. Cordes, Christopher W. Platt, John F. Carpenter, 
Theodore W. Randolph. Selective domain stabilization as a strategy to reduce fusion protein 
aggregation.) 
 
4.1 Introduction 
Fusion proteins are a growing class of protein therapeutics 
1
. These are molecules which 
combine unrelated proteins, or domains from unrelated proteins, to create a new therapeutic 
protein. Etanercept, romiplostim, abatacept and rilonacept are all examples of current FDA-
approved fusion proteins, and there are others in late-stage clinical trials 
2
. Compared to other 
protein therapeutics, there can be several benefits to fusion proteins, such as extended serum 
half-life
3, 4
 or added functionality
 5
. Despite these benefits, there are also inherent challenges in 
creating stable formulations of fusion proteins. The increasing numbers of fusion proteins in 
development make it desirable to understand and improve fusion protein formulations. 
As with other therapeutic proteins, fusion proteins are susceptible to instabilities such as a 
propensity to aggregate that can negatively impact production and product quality
6
. Aggregation 
has been implicated in causing adverse immune responses in patients
 7, 8, 9
. Aggregation also can 
cause loss of protein during manufacture, transportation and storage
 10, 11, leading to decreased 
product yields and profits
 12
.  
The Lumry-Eyring model has been extensively used as the basis for the understanding of 
protein aggregation
 11, 13, 14
. Roberts et al. have described an extended model of non-native 
protein aggregation composed of six steps
 15, 16
, although any specific protein need not go 
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through all steps in order to form aggregates.  The initial step involves some conformational 
change to form an aggregation-competent species and the second step involves the association of 
aggregation-competent monomers to a reversible aggregate. Later steps describe further 
conformational changes that result in irreversibility of the initial aggregate and then growth to 
larger aggregates. The two initial steps are essentially the Lumry-Eyring framework of protein 
aggregation, which may be depicted schematically as 
11, 13, 15
:  
(1) N ↔ N* 
(2) 2N* ↔ A2 
 
where N* is an aggregation competent conformation of the native protein and A is the initial 
aggregate. The rate of the initial step is impacted by the conformational stability of the protein, 
which is measured experimentally as the free energy of unfolding (ΔGunf); larger ΔGunf values 
indicate proteins or protein domains with increased conformational stability and thus lower 
equilibrium populations
11 of aggregation-competent species N*. 
The rate constant for the association step is affected by the energetics of protein-protein 
interactions, i.e., colloidal stability. Experimentally, second osmotic virial coefficient values 
(B22) are used to reflect the net contribution of all protein-protein interactions (e.g. hard sphere, 
electrostatic, Van der Waals). Positive B22 values indicate that protein-protein self interactions 
are repulsive, whereas negative B22 values indicate self-interactions are attractive. Either the 
unfolding or association step can be rate limiting in the formation of the initial aggregates 17, 
depending on the solution conditions.  Both steps are potential targets for strategies to reduce 
protein aggregation. For example, excipients may be added that increase ΔGunf, and solution 
conditions such as pH may be adjusted to increase repulsive protein-protein interactions
17
. 
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Fusion proteins face an additional set of unique stability challenges that can contribute to 
their propensity to aggregate. Unlike naturally-occurring multidomain proteins, the individual 
domains in fusion proteins have not co-evolved for stability and may lack stabilizing intra-
domain interactions, thus reducing ΔGunf. Formulation conditions that favor the conformational 
stability of one domain may not adequately stabilize other domains 
18
. In addition, under 
solutions conditions where the domains have different net charges, large dipoles may be created, 
adding additional attractive protein-protein interactions and colloidally destabilizing the protein 
solution
 18
.  
Previous work by our group on an Fc- fusion protein showed increases in aggregation 
rates that correlated with decreased domain conformational stability
 18
. The model protein for 
those studies was Fc-CTLA-4, an IgG Fc domain fused with the extracellular domain of CTLA-4 
(human cytotoxic T-lymphocyte associated factor). During accelerated stability studies, Fc-
CTLA4 exhibited markedly different aggregation rates with only a small shift in pH. Conditions 
that increased aggregation also reduced the conformational stability of the CTLA-4 domain and 
the CH2 region of the Fc domain. Thermally- and chaotrope-induced denaturation studies showed 
that these two domains were the least conformationally stable of the protein’s domains, leading 
to the conclusion that domain conformational instability was the primary driving force for Fc-
CTLA4 aggregation.  
These previous findings now lead us to develop two hypotheses regarding fusion protein 
behavior. We hypothesize that the overall stability and aggregation behavior of multi-domain 
proteins can be controlled by choosing formulation conditions that favor the stability of the least 
conformationally stable domain, and that selective stabilization of this domain will reduce 
overall aggregation rates of the entire fusion protein. In this work, we use protein comprising a 
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fusion of human serum albumin with human growth hormone (HSA-hGH) as a model system to 
determine the impact of domain stability on overall protein stability.  
To test our hypotheses, we measured the conformational stabilities of the least 
conformationally stable domain and of the complete fusion protein. In addition, we measured B22 
values for the fusion protein. During these studies, cosolute addition was investigated as a way to 
achieve selective domain conformational stabilization through the preferential binding of the 
cosolutes to the native state
 11
. HSA is the least conformationally stable domain in the 
thermodynamic sense because it has a lower free energy of unfolding  than  hGH. The free 
energy of unfolding for hGH has been reported as 60.7 ± 4.2 kJ/mol and 62.3 kJ/mol at pH 7.5
 19, 
20 
and 62.3 kJ/mol at pH 6.0 
21
.   These relatively high stabilities can be compared to 17.2 ± 4.2 
kJ/mol at pH 7.4 and 14.6 ± 1.3 at pH 5.3 for HSA, as reported by Faruggia and Pico
 22
. Based on 
these data, the HSA domain was chosen as the target for selective stabilization. Additionally, 
since there are other HSA fusion proteins that have either been patented or commercially 
developed to varying degrees
 25, 26
, this approach has the potential to be useful on a platform 
level. Conformational and colloidal stability of the fusion protein with the cosolute were 
measured to determine cosolute influence on overall protein stability.  
Octanoic acid was used as a cosolute to selectively stabilize the HSA domain. Although 
HSA binds long chain fatty acids with a higher affinity than octanoic acid
 27, 28, octanoic acid was 
chosen for its historical role as a stabilizer during heat treatment of HSA 
29, 30
, and for its higher 
solubility compared to long chain fatty acids
 30
. Most of association constants
 28, 29, 31 that have 
been measured under solution conditions similar to those used in the present study are on the 
order of 10
6
 M
-1
, although a binding constant of 2.6 x 10
4
 M
-1
 has also been reported 
27
. Binding 
of octanoic acid to HSA is consistent with a single binding site in the HSA sub domain IIIA
 28, 29
, 
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which is a very active binding site on the molecule
32
. Based on the Wyman linkage function
 33, 34
, 
one would expect an increase in HSA conformational stability when octanoic acid binds to the 
protein. This increase in stability is presumably reflected in the 8 °C increase in apparent Tm at 
pH 7.4 seen with a 5:1 molar ratio of octanoic acid to protein
 29
, although apparent Tm values 
reflect a mixture of both aggregation and unfolding. 
 
4.2 Materials and Methods 
4.2.1 Stock protein preparation 
The HSA-hGH fusion protein was donated by Teva Biopharmaceuticals (Rockville, MD) 
and recombinant HSA was donated by Novozymes (Bagsvaerd, Denmark). Protein was dialyzed 
into the buffer of choice: 10 mM sodium phosphate (pH 7.0) or 10 mM sodium acetate (pH 
5.0).All buffers contained 0.01% sodium azide as an antimicrobial agent. The hGH was 
expressed and purified in-house as described previously
 35
 
 
 and dialyzed into one of the above 
buffers for experimentation.  
 
4.2.2 Addition of octanoic acid 
Octanoic acid stock was prepared at a concentration of 4 mM in the buffer of choice prior 
to each experiment. Appropriate volumes of stock were added to protein samples to obtain either 
a constant 5:1 molar ratio of octanoic acid to protein, or a bulk concentration of 0.5 mM octanoic 
acid. When the molar ratio of octanoic acid to protein is held constant, the concentration of 
octanoic acid must necessarily be different at the different protein concentrations required for 
various experimental techniques. In addition, due to the different molecular weights of HSA and 
HSA-hGH, bulk concentrations of octanoic acid will be different at a constant octanoic 
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acid/protein ratio. A comparison of molar ratio versus octanoic acid concentration for HSA and 
HSA-hGH across techniques is given in Table 4-1. All experimental results are reported in initial 
mM concentration of octanoic acid.  
  
4.2.3 Aggregation studies 
Protein samples, either HSA, hGH, or HSA-hGH, were incubated at an initial 
concentration of 5 mg/mL at 50 °C in buffer alone or with octanoic acid. Octanoic acid 
concentrations were maintained at either 0.5 mM in the bulk or a 5:1 molar ratio of octanoic acid 
to protein. Size exclusion chromatography was used to measure the amount of monomer 
remaining after incubation as well as to detect the presence/amount of soluble aggregates. Prior 
to analysis by size exclusion-high performance liquid chromatography (SEC-HPLC), samples 
were centrifuged for five minutes at 15400g to remove insoluble aggregates.  A Beckman 
System Gold HPLC (Beckman Coulter, Brea, CA) with a 717plus autosampler (Waters 
Technologies Corporation, Milford, MA) and a G3000SWXL size exclusion column (Tosoh 
Bioscience LLC, Montgomeryville, PA) were used. The mobile phase was 100 mM sodium 
phosphate, 200 mM sodium chloride (pH 7.0) for the HSA-hGH samples and 20 mM sodium 
phosphate, 100 mM sodium chloride (pH 6.8) for the HSA samples with a flow rate of 0.6 
mL/min. Column elution was monitored by UV absorbance at 280 nm and Bomem Grams 
software version 7.0 was used to integrate the peaks. Concentration of the peak species was 
calculated from the integrated peak area. For analysis of apparent first order rate constants for 
aggregation, the only points used were those where at least 90% of initial monomer remained. 
Apparent first order reaction rate constants were determined from the slope of a plot of the  
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Experiment 
 
 
 
Protein 
concentration  
HSA HSA-hGH 
Octanoic acid 
concentration 
(mM) 
Molar ratio 
of octanoic 
acid to 
protein 
Octanoic acid 
concentration 
(mM) 
Molar ratio of 
octanoic acid to 
protein 
Aggregation 
Studies 
5 mg/mL 0.38 5:1 0.28 5:1 
0.5  6.6:1 0.5 8.9:1 
Far UV 
CD/Intrinsic 
fluorescence 
0.1 mg/mL 0.008 5:1 0.006 5:1 
0.5  330:1 0.5  445:1 
Near UV 
CD 
1 mg/mL --- --- 0.056 5:1 
--- --- 0.5  44.5:1 
Static Light 
Scattering 
1-3 mg/mL 0.076 – 0.230 5:1 0.056 – 0.170 5:1 
0.5  33:1 – 11:1 0.5  44.5:1 – 15:1 
 
Table 4-1: Comparisons of mM octanoic acid concentrations to molar ratios of octanoic acid to 
protein at varying experimental protein concentrations 
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natural log of monomer concentration versus time and represent the average of rate constants 
from three incubation experiments. Errors represent the standard deviation. 
 
4.2.4 Static light scattering 
HSA-hGH was dialyzed into 10 mM sodium phosphate (pH 7.0) or 10 mM sodium 
acetate (pH 5.0) at five different target concentrations: 1, 1.5, 2, 2.5 and 3 mg/mL. 
Samples were filtered using either a 0.02 um inorganic filter (Whatman Anotop, Kent, UK) for 
the blank (buffer only) or a 0.1 um filter for samples containing protein. For samples containing 
octanoic acid, the octanoic acid stock was added to the filtered protein sample as described 
above. The static light scattering of the samples was measured with a Brookhaven light 
scattering system (Holtsville, NY) with a 633 nm laser. The detector aperture was set to 1 cm. 
The actual sample concentrations after dialysis and filtration were determined from the 
absorbance at 280 nm following completion of the experiments. During all experiments, the 
temperature of the sample chamber was set to 25 °C using a water bath connected to the sample 
chamber. Equations 1 and 2 were used to calculate the osmotic second virial coefficient (B22) 
36
. 
B22 values are reported as the average of three experiments ± standard deviation. Equation 1 can 
be used to determine the B22 from a graph of excess Raleigh ratio versus concentration, where 
Mw is the mass averaged molecular weight, R90 is the excess Rayleigh ratio at 90°, and K is the 
optical constant described by Equation 2. In Equation 2, n0 is the solvent refractive index, dn/dc 
is the refractive index increment, λ is the incident wavelength and NA is Avogadro’s number. For 
these calculations, a dn/dc value of 0.185 was used
 37
.  
 
      
𝐾𝑐
𝑅90
=  
1
𝑀𝑤
+  2 𝐵22 𝑐  (1) 
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4.2.5 Fluorescence spectroscopy 
Fluorescence spectroscopy was used to measure the free energy of unfolding (ΔGNU) of 
the proteins according to the chaotrope perturbation method described previously
 38
. Intrinsic 
fluorescence of HSA and HSA-hGH were monitored as a function of urea or guanidine 
hydrochloride concentration at 25 °C. Protein samples (either alone or with excess molar 
octanoic acid as noted) at a concentration of 0.1 mg/mL were incubated for 12 hours with urea 
concentrations varying from 0-9.5 M or with guanidine hydrochloride concentrations from 0-6.5 
M. Samples were prepared by mixing stock protein, buffer and buffer with 10 M urea or 7 M 
guanidine hydrochloride to generate the range of chaotrope concentrations for the incubation. 
Stock buffers with chaotrope were freshly prepared for each incubation. Chaotrope 
concentrations were determined from the difference in refractive index between the buffer and 
the buffer with chaotrope
 38
. After incubation, each sample was excited with 293 nm wavelength 
light and the emission spectrum from 300-400 nm was recorded using an Aminco Bowman 
Series 2 fluorescence spectrophotometer (SLM Aminco, Urbana, Illinois). For each emission 
scan, the center of spectral mass (CSM) was calculated using Equation 3: 
 
        
 
  
 
             
where Fi is the fluorescence intensity and vi is the wavenumber. Unfolding curves were 
generated by graphing the center of spectral mass versus denaturant concentration. The 
incubations were repeated a total of three times to generate each unfolding curve. Free energies 
𝐾 =  
4𝜋2𝑛0
2(𝑑𝑛 𝑑𝑐 )2
𝑁𝐴𝜆4
  (2) 
CSM =  
 𝐹𝑖𝑉𝑖
 𝐹𝑖
  (3) 
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of unfolding for HSA were calculated in Sigma Plot (Version 7.0, 2001) by a non-linear least 
squares fit to a two state model of protein unfolding using Equation 4 as previously described
 39
: 
 
 
 
In this equation, Y0 is the center of spectral mass value, kN and kU are the slopes of the baselines 
of the native and unfolding states respectively, bN and bU are the intercepts of these baselines, T 
is temperature, R is the molar gas constant and ΔGNU is the free energy of unfolding. For 
chaotrope-induced unfolding, ΔGNU can be described by Equation 5
  39
.  
 
 
ΔGNU(D) is the free energy of the unfolding in the chaotrope, ΔGNU(H20) is the free energy of 
unfolding at a zero chaotrope concentration, [D] is the concentration of the chaotrope and m 
reflects the sensitivity of ΔGNU to chaotrope concentration (i.e., dΔGNU/d[D]). 
 
4.2.6 Thermally Induced Unfolding Monitored by Circular Dichroism 
Secondary and tertiary structural changes of HSA, hGH and HSA-hGH were inferred 
from far- and/or near-UV circular dichroism (CD) spectra, obtained as a function of temperature 
using a Chirascan Plus CD spectrometer (Applied Photophysics, Surrey, UK) fitted with a Peltier 
temperature control. The protein secondary structure was measured with far UV scans from 200-
250 nm, at a protein concentration 0.1 mg/mL and quartz cell path length of 1 mm. Fusion 
protein tertiary structures were measured with near UV scans from 240-350 nm using a 10 mm 
pathlength quartz cuvette at a protein concentration of 1 mg/mL. For thermally-induced 
∆𝐺𝑁𝑈 𝐷 =  ∆𝐺𝑁𝑈 𝐻2𝑂 +  𝑚[𝐷]  (5) 
Y0 =  
 kN  D + bN  +  kU  D + bU  exp (
−ΔG NU
RT
)
1+exp (
−ΔG NU
RT
)
  (4) 
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unfolding scans, a one degree C step was used, with a one minute hold at each temperature. An 
unfolding curve was measured at each wavelength in the range of interest (200-250 nm or 240-
350 nm) during thermal unfolding. The loss of tertiary structure was determined by following the 
signal of the tryptophan (295 nm) or tyrosine (280 nm) residues. Octanoic acid was added to 
protein samples in a 5:1 molar ratio of octanoic acid to protein (6 μM) or at a bulk concentration 
of 0.5 mM to investigate the effects of octanoic acid on protein structure and thermal stability. 
The apparent midpoints of unfolding (Tm) were calculated using the Global Analysis software 
(Applied Photophysics, Surrey, UK), with the average values of three replicates ± the standard 
deviation listed in the results.  
 
4.3 Results 
4.3.1 Aggregation Studies 
HSA-hGH aggregates much more rapidly at pH 5.0 than at pH 7.0 (see Table 4-2) during 
incubation at 50 °C. Under the same solution conditions used for the HSA-hGH studies, HSA 
aggregation rates are lower than those of HSA-hGH. Incubation of HSA at pH 5.0 in 10 mM 
sodium acetate buffer results in an almost no loss of monomer, as seen in Figure 4-1. 
Additionally, at pH 7.0, no aggregation of HSA is detected during the 17 days of incubation at 50 
°C. However, at pH 5.0, the aggregation behavior of hGH appears to be similar to that of the 
HSA-hGH fusion protein. At pH 7.0, hGH aggregation proceeds more slowly than at pH 5.0. 
The addition of octanoic acid results in a large reduction of HSA-hGH aggregation rates 
(Figure 4-2), but does not reduce the aggregation rates of either HSA or hGH. No changes were 
observed in the aggregation rate of HSA with the addition of 0.38 mM octanoic acid (5:1 molar 
ratio) or 0.5 mM octanoic acid at pH 5.0. Addition of octanoic acid does not reduce hGH  
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 Apparent first order reaction rate constants (day 
-1
) measured at 50 °C 
Protein pH 7.0  pH 7.0 + 0.5 mM 
octanoic acid 
pH 5.0  pH 5.0 + 0.5 mM 
octanoic acid 
HSA-hGH 0.01 ± 0.002 0.004 ± 0.004 0.77 ± 0.16 0.002  ± 0.001 
HSA Zero Zero Zero N/D 
hGH 0.1 ± 0.02 0.17 ± 0.02 0.6 ± 0.2 0.7 ± 0.2 
Table 4-2: Apparent first order reaction rate constants (day 
-1
) for the three proteins under 
various solution conditions. The rate of HSA aggregation detected was zero, within error at both 
pH 7.0 and pH 5.0. Addition of octanoic acid reduced the aggregation of HSA-hGH, but did not 
appear to reduce the aggregation of HSA or hGH alone.  
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Figure 4-1: Percent of initial monomer remaining versus time for HSA (Panel A) and hGH 
(Panel B) incubation at pH 5.0 and 50 °C for the protein alone () and with ()octanoic acid. 
Data points represent the average value ± the standard deviation.  
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Figure 4-2: Percent of initial monomer remaining versus time during HSA-hGH incubation at 
pH 5, 50 °C for the protein alone (), with 0.28 mM octanoic acid () and with 0.5 mM 
octanoic acid(●). Aggregation of HSA-hGH is reduced as octanoic acid concentration increases, 
as evidenced by the increased amounts of monomer remaining in solution after incubation when 
octanoic acid is present. Data points represent the average value ± the standard deviation. 
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aggregation. At pH 5.0, in the presence of 0.5 mM octanoic acid, the apparent first order reaction 
rate constant is essentially the same as the rate constant without octanoic acid present. At pH 7.0, 
the rate of hGH aggregation in the presence of 0.5 mM octanoic acid appears to increase slightly 
compared to at pH 7.0 alone. 
Additionally, longer incubations of HSA-hGH at pH 5.0 and 50 °C with and without 
octanoic acid showed differences in the amount and type of aggregate species present. For HSA-
hGH in the absence of octanoic acid, only 15% of the initial monomer remained after five days 
and no soluble aggregates were detected. The samples containing HSA-hGH and 0.28 mM 
octanoic acid had 30% of the initial monomer remaining, with a small amount of soluble 
aggregates present as well, as shown in Figure 4-3.  
 
4.3.2 Measurement of B22 by Static Light Scattering 
For all HSA-hGH samples at 25 °C, the net protein-protein self interactions are repulsive, 
as evidenced by the positive values for the second virial coefficients in Table 4-3. When octanoic 
acid is added to HSA-hGH at pH 5.0 at a 5:1 molar ratio of octanoic acid (equivalent to an 
octanoic acid concentration range of 0.078 to 0.17 mM, see Table 4-1), the magnitude of the 
repulsive interaction increases. However, at pH 7.0, the addition of octanoic acid does not appear 
to change the net interaction. The self interactions remain repulsive and the magnitudes of these 
interactions remain the same as the samples without octanoic acid. Static light scattering 
measurements of HSA-hGH with a constant 0.5 mM octanoic acid at pH 5.0 indicate that the 
additional octanoic acid does not change the self interactions significantly compared to the 
experiments where the molar ratio was held constant (data not shown).  
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Figure 4-3: A) SEC chromatogram of HSA-hGH (solid line) and HSA-hGH with 0.28 mM 
octanoic acid (5:1 molar ratio) (dotted line) at time zero and HSA-hGH (dashed line) and HSA-
hGH with 0.28 mM octanoic acid (dash-dotted line) post 5 day, 50 °C incubation. B) Close up of 
soluble aggregate peak. Addition of octanoic acid reduces the extent of monomer loss (A) and 
changes the distribution of aggregate species, with soluble aggregates being detected when 
octanoic acid is present (B).    
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pH  SVC x 10
4
 
(mL mol g
-2
) 
SVC x 10
4
 (mL mol g
-2
) 
with 5:1 octanoic acid 
5.0 0.4 ± 2.1 6.0 ± 0.4 
7.0 3.1 ± 0.9 2.9 ± 1.4 
 
Table 4-3: Osmotic second virial coefficients for HSA-hGH calculated from static light 
scattering with and without octanoic acid. Values represent the average of three replicates ± the 
standard deviation.  
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4.3.3 Protein conformational stability 
HSA-hGH unfolding curves exhibit two transitions during chaotrope denaturation. 
Although it is difficult to calculate the free energies of HSA-hGH unfolding due to the non-zero 
slope of the baseline at urea concentrations greater than 9.5 M (shown in Figure 4-4), it is still 
possible to compare the onset of unfolding and the transitions that are present as a function of 
urea concentration. Although guanidine hydrochloride is a stronger chaotrope than urea, urea is 
used here because chloride ion binding may interfere with the binding of other molecules (e.g., 
octanoic acid) to HSA
31
.  Previously, the free energy values for guanidine hydrochloride 
denaturation of HSA-hGH were reported as 16.7 ± 0.8 kJ/mol for the first transition and 24.6 ± 
2.5 kJ/mol for the second transition
40
. In the current study, at pH 7.0 and 25 °C, the first HSA-
hGH unfolding transition begins at approximately 5 M urea, and the second transition begins at 
approximately 7 M urea. Addition of 0.006 mM octanoic acid does not change the transitions 
with regard to denaturant concentration at onset of unfolding or curve shape (Figure 4-4). The 
first unfolding transition at pH 5.0 also begins at 5 M urea, and the unfolding curve is similar in 
shape to the unfolding curve at pH 7.0.  
 Chaotrope-induced denaturation curves for HSA exhibit only one unfolding transition 
and the onset of this transition coincides with that of the first transition of the HSA-hGH fusion 
(Figure 4-5), as observed previously
 40
. The free energy of unfolding is 20.7 ± 3.6 kJ/mol at pH 
7.0. Previously, the conformational stability of HSA has been shown to be nearly  independent of 
pH between pH 7.4 and pH 5.3, with a ΔGNU value of 17.1 ± 4.2 kJ/mol at pH 7.4 and a ΔGNU 
value of 14.6 ± 1.3 kJ/mol at pH 5.3 
22
.The onset of unfolding for HSA increases by an 
increment of 2 M urea with the addition of 0.5 mM octanoic acid at pH 5.0, but the baseline at 
high urea concentrations is not sufficient for calculations of ΔGunf. Assuming the m value (which  
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Figure 4-4: Representative plots of the center of spectral mass versus urea concentration during 
fluorescence spectroscopy monitored denaturation of HSA-hGH by urea at pH 7.0 either with 
() or without () 0.006 mM octanoic acid and at pH 5.0 (). No change in the onset of 
denaturation or with regard to the two transitions is observed between the pH two conditions or 
with the addition of octanoic acid. 
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Figure 4-5: Denaturation of HSA () and HSA-hGH () at pH 7.0 by guanidine hydrochloride 
monitored by fluorescence spectroscopy, showing the center of spectral mass versus molar 
chaotrope concentration.  Onset of HSA unfolding occurs at the same GndHCl concentration as 
that of the first transition of HSA-hGH.  
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was reported as 15.0 kJ/mol
21
)  remains unchanged with the addition of octanoic acid, the 
observed  2M increase in the concentration of urea at the onset of unfolding represents an 
increase in stability, ΔΔGNU, of 30 kJ/mol.  
 
4.3.4 Protein structure and apparent midpoints of unfolding 
The far UV CD scans from 200-250 nm show that HSA-hGH has a predominantly α-
helical structure and that secondary structure is not affected by the addition of 0.5 mM octanoic 
at either pH condition (Figure 4-6). The structure of the HSA domain was also unaffected by the 
addition of 0.5 mM octanoic acid at pH 5.0 (data not shown). Values for the apparent midpoint 
of the unfolding transition (Tm) are listed in Table 4-4. An increase in HSA-hGH Tm is seen upon 
addition of 0.5 mM octanoic acid; the apparent Tm increases by one degree at pH 5.0 and by 
approximately four degrees at pH 7.0. The apparent Tm for HSA increases in the presence of 0.5 
mM octanoic acid at pH 5.0; however, there is no significant change to the apparent Tm for hGH 
under these conditions. Apparent Tm values are not equilibrium values.  The protein aggregates 
during heating, and thus the apparent Tm values reflect both unfolding and aggregation 
processes
41
.  
No change in the tertiary structure of HSA-hGH is observed by near UV CD after the 
addition of octanoic acid at 25 °C (data not shown). The apparent Tm for the loss of HSA-hGH 
tertiary structure could not be calculated due to the signal from the aggregates, but the onset of 
thermal denaturation occurred at 63 °C without octanoic acid at pH 5.0 (Figure 4-7). A two 
degree increase in the temperature of the onset of unfolding is seen with the addition 0.5 mM 
octanoic acid at pH 5.0. 
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Figure 4-6: Far UV CD of HSA-hGH comparing the secondary structure of samples at pH 5.0 
with 0.5 mM octanoic acid (dotted) and without (solid) to samples at pH 7.0 with (dash-dotted) 
and without (dashed) 0.5 mM octanoic acid. Addition of octanoic acid does not noticably change 
the protein secondary structure.  
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Protein pH Tm (°C) Tm in the presence of 0.5 
mM octanoic acid (°C) 
HSA-hGH 5.0 69.0 ± 0.1 70.4 ± 0.1 
HSA-hGH 7.0 69. 3 ± 0.2 73.9 ± 0.5 
has 5.0 70.0 ± 0.3 72.0 ± 0.1 
hGH 5.0 66.3 ± 1 67.4 ± 2.3 
Table 4-4: Tm values for HSA-hGH, HSA and hGH with and without octanoic acid. Addition of 
0.5 mM octanoic acid increases the conformational stability of HSA-hGH and HSA. In order to 
bridge the different octanoic acid concentrations used for aggregation studies versus 
conformational stability studies, the Tm was also measured for HSA and HSA-hGH at 
concentrations of 0.38 mM and 0.28 mM octanoic acid concentrations. Tm values under these 
conditions are 70.1 ± 0.1 °C for HSA-hGH and 73.2 ± 1.7 °C for HSA. 
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Figure 4-7: Loss of HSA-hGH tertiary structure during thermal denaturation at pH 5.0, followed 
by near UV CD spectroscopy at 295 nm (A) or 280 nm (B) of the protein alone (solid line) or 
with 0.5 mM octanoic acid (dotted). The onset of the thermal transition is shifted from 63 °C to 
65 °C with 0.5 mM octanoic acid.  
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4.4 Discussion 
Human growth hormone is a therapeutic protein used to treat endogenous growth 
hormone deficiency in both children and adults
 24
. HSA-hGH fusion proteins were created with 
the goal of increasing the circulation half-life of hGH
 25
. Although HSA aggregates more slowly 
than hGH at both pH 5.0 and pH 7.0, the addition of the HSA domain to hGH does not result in 
improved kinetic stability of the therapeutic molecule against aggregation. The HSA-hGH fusion 
protein aggregates much more rapidly than HSA alone at pH 5.0 and aggregates more at pH 7.0 
as well, with rate constants similar to those exhibited by  hGH. However, although addition of 
HSA to hGH does not result in improved stability against aggregation, it does appear to stabilize 
the hGH structure within the fusion protein, as HSA-hGH shows increased resistance to thermal 
melting compared to hGH alone.  
Octanoic acid presumably increases the conformational stability of HSA as evidenced by 
the previously reported increase in Tm in the presence of octanoic acid
 29
,  and it is used during 
viral inactivation steps to protect against the precipitation of HSA
 30
. Octanoic acid also increases 
the apparent Tm of HSA-hGH. Even though the aggregation rates of HSA-hGH are more similar 
to the aggregation rates of hGH than to the aggregation rates of HSA, HSA-hGH aggregation is 
reduced and the apparent Tm is increased with addition of 0.28 mM octanoic acid. Repulsive 
HSA-hGH protein-protein interactions also increase with the addition of octanoic acid, as 
evidenced by the increase in B22.  
Under the solution conditions tested, HSA is relatively stable against aggregation. Even 
in the absence of octanoic acid, aggregation for HSA alone was much slower than that of the 
fusion protein. No changes in aggregation rates of HSA alone were detected at the different pH 
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conditions or with the addition of octanoic acid, even though increases in conformational 
stability were seen with the addition of octanoic acid.  
Although the addition of octanoic acid increases both the colloidal stability and stability 
against thermal unfolding of HSA-hGH, it is apparent that colloidal instability dominates the 
aggregation behavior. This can be seen from the behavior of the fusion protein at pH 5.0 and pH 
7.0. No significant changes in the conformational stability of HSA-hGH were observed between 
pH 5.0 and pH 7.0; the onset of unfolding during chaotrope denaturation occurs at the same urea 
concentrations and the unfolding transitions overlap. However, the aggregation rate at pH 5.0 
was an order of magnitude larger than the aggregation rate at pH 7.0. Consistent with the 
dominant influence of colloidal interactions, net interactions were more attractive at pH 5.0 than 
at pH 7.0.  
Similar dependence on colloidal stability was seen previously with GCSF where under 
two pH conditions nearly identical conformational stabilities were observed but dramatic 
differences in aggregation rates correlated with B22 values
 17
. The aggregation of recombinant 
human interleukin-1 receptor antagonist (rhIl1-ra) also is driven by colloidal instabilities
 42 
. 
rhIl1-ra conformational stability was independent of formulation conditions, but the colloidal 
stability was reduced at low ionic strengths. The attractive protein self interactions were not 
screened at low ionic strength, resulting in the formation of dimers and trimers
 42
. Still, colloidal 
stability is not always the driving force for aggregation. Increases in aggregation that correspond 
to activation energy decreases for structural transitions have been seen both for large, 
multidomain proteins
  18  as well as smaller proteins (~ 50 kDa) with a single unfolding transition 
43 , 44
.To help understand the contribution so individual domains to the stability of fusion 
proteins, , ΔGNU values for individual protein domains may be measured.  In contrast, however, 
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B22 values cannot be ascribed to individual domains. Furthermore, it is unlikely that the colloidal 
stability of a fusion protein formulation could be predicted from the colloidal stability of 
formulations of individual domains. B22 includes the effects of electrostatic, steric and short 
range interactions and is impacted by charge distribution and protein geometry
 45
. In other 
multidomain proteins, such as antibodies, it has been shown that the self association can change 
significantly with relatively small changes in amino acid sequence. For example, two 
monoclonal antibodies were studied that only differed in sequence in the Fab domain
 46
; mAb1 
self associated while mAb2 did not. By swapping the charged residues in mAb1 with the 
residues at the corresponding position in mAb2, the self association behavior of mAb1 was 
reduced
 46 
. Since mAb1 and mAb2 only differed in sequence in the Fab region, it would be 
expected by analogy that the colloidal properties of a fusion protein would differ depending on 
the domain partnered with HSA. Better predictive models of colloidal stability would be useful 
to help understand the changes in colloidal stability that may occur with a fusion protein 
compared to the therapeutic protein alone.  
 
4.5 Conclusions 
In contrast to our original hypothesis, we found that stabilizing the HSA domain does not 
reduce the aggregation of HSA-hGH. However, increasing colloidal stability reduces aggregation 
significantly. Additional work is needed to determine the applicability of these results across the 
HSA fusion class of proteins.  
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CHAPTER 5 
 
SELECTIVE DOMAIN STABILIZATION AS A STRATEGY TO REDUCE HSA-GCSF 
AGGREGATION RATE 
 
 
5.1 Introduction 
 
The development of recombinant therapeutic proteins has provided new treatments for 
many serious conditions, including endogenous protein deficiencies, cancer and autoimmune 
disorders
 1
. In order to be successful drug candidates, these complex molecules require 
stabilization by formulation excipients so that degradation rates are minimized from 
manufacturing through transportation to administration to patients 
2,3
. Both chemical and 
physical instabilities of therapeutic proteins have the potential to negatively impact product 
quality
 3
; this work focuses the aggregation, the most commonly observed physical instability. 
Much work has been done to investigate the stability and aggregation behaviors of protein 
therapeutics
 3, 4, 5, 6
. Aggregation of protein products is a concern for several reasons. Aggregation 
can lead to loss of product during manufacture, storage and shipping 
7, 8
.  Moreover, if aggregates 
are administered to patients, they may trigger patient immune responses
 9, 10, 11
. These potential 
adverse immune responses include anaphylactic shock and the production of anti-drug antibodies 
which can increase drug clearance and potentially cross react with endogenous protein
 12, 13
. 
Aggregation rates can be modulated by both a protein’s conformational stability and its 
colloidal stability in solution 
8
. Conformational stability refers to the thermodynamic stability of 
the protein’s proper three-dimensional folded structure, whereas colloidal stability refers to the 
energetics of protein-protein self interactions between molecules. Protein-protein interactions are 
repulsive in colloidally stable systems.  For the purposes of this report we use the free energy of 
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unfolding, ΔGNU, for HSA-GCSF as a measure of its conformational stability, and the osmotic 
second virial coefficient, B22, for HSA-GCSF as a measure of its colloidal stability
 8
. 
 Granulocyte colony stimulating factor (GCSF) is an important therapeutic and is used as 
to increase the production of white blood cells in patients undergoing chemotherapy
 14
. Its 
propensity to aggregate has been extensively studied and characterized. Previous studies
 4
 
showed that rate of aggregation of 1.5 mg/mL GCSF in solution at near-physiological conditions 
(pH 6.9 in phosphate buffered saline, 37 °C) is rapid, with a reaction rate of 7.3 ± 0.6 μmol L-1 
day
-1
 and an apparent reaction order that is second-order in protein concentration. However, an 
apparent first order dependency on protein concentration has also been observed at GCSF 
concentrations greater than 2.5 mg/mL (pH 7.0, 0.1 M MOPS),
 15
 with aggregation under these 
conditions involving a conformationally altered monomer state
14
. Both conformational and 
colloidal instabilities play a role in the aggregation of GCSF under varying solution conditions
 16
. 
Addition of sucrose, a molecule that is preferentially excluded from the surface of proteins
 17
, 
increases the conformational stability of GCSF and reduces its rate of aggregation
 4
. 
Furthermore, because of this stabilizing effect, sucrose partially counteracts the acceleration of 
GCSF aggregation caused by benzyl alcohol
 18, 19
. Protein-protein interactions that impact the 
colloidal stability of proteins can be modified by the choice of solution pH. GCSF is more 
colloidally stable at pH 3.5 than at pH 7.0 (i.e. protein-protein interactions are more repulsive) 
and aggregates much less rapidly at pH 3.5
 4
, even when protein tertiary structure is perturbed by 
benzyl alcohol
 19
. Increasing the formulation ionic strength, which screens repulsive protein-
protein electrostatic interactions at pH 3.5, results in an increased aggregation rate
 16
. 
GSCF aggregation is of interest given a current trend for development of 
biopharmaceutical products with increased patient convenience and compliance. These efforts 
 101 
 
include the development of strategies to increase the circulation half-life of the drug product and 
thus reduce the administration frequency
 20, 21
. One method of increasing the circulation half-life 
is to create a fusion protein, co-expressing the drug molecule with another protein such as the Fc 
domain of an antibody
 22
 or human serum albumin (HSA)
 21, 23,
. A fusion protein of GCSF and 
HSA has been developed to increase the circulation half-life of GCSF
 24
 and this fusion protein is 
the focus of the current research.  
There are added stability challenges involved in the formulation of fusion proteins. 
Because the individual fusion domains did not co-evolve, they may lack built-in inter-domain 
interactions that contribute favorably to native-state stability. Also, solution conditions that 
stabilize one domain may not adequately stabilize the other domain(s) of the fusion protein. 
However, because aggregation of proteins in generally thought to result from their (partial) 
unfolding
 8, 25
, we hypothesized that the aggregation rate of fusion proteins can be reduced by 
increasing the conformational stability of the least-stable domain
 26
. In the case of HSA fusion 
proteins, the addition of octanoic acid, an HSA ligand, is one potential strategy to selectively 
stabilize the HSA domain 
8, 17, 27
. HSA was chosen as the target for selective domain stabilization 
because it  has a lower free energy of unfolding value than GCSF (ΔGNU for HSA is 
approximately 22.0 ± 0.5 kJ/mol, compared to 39.7 ± 2.1 kJ/mol for GCSF)
 16, 28
 and is thus 
presumed to be the least conformationally stable domain in HSA-GCSF.  In addition, we 
hypothesized that the addition of the less thermodynamically stable HSA domain will increase 
aggregation rate for the resulting fusion protein compared to that for GCSF alone. To test these 
hypotheses, the aggregation rates, aggregation reaction orders and stability behavior of HSA-
GCSF with and without selective domain stabilization were investigated and compared to the 
aggregation rates of both GCSF
 4, 16
 and another HSA fusion, HSA-hGH
 29
. Conformational 
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stability was investigated using chaotrope- and thermally-induced denaturation, whereas 
colloidal stability was determined by static light scattering and zeta potential measurements. 
Octanoic acid was used as a small molecule ligand for the stabilization of HSA
 30, 31
. 
 
5.2 Materials and Methods 
5.2.1 Stock protein preparation 
HSA-GCSF was donated by Teva Biopharmaceuticals (Rockville, MD) and stored frozen 
at -80 °C. For experimentation, HSA-GCSF was thawed and dialyzed into 10 mM sodium 
phosphate buffer (pH 7.0). For experiments where sodium chloride was added, HSA-GCSF was 
dialyzed into 10 mM phosphate, 150 mM NaCl buffer (pH 7.0) (PBS). The concentration of 
HSA-GCSF after dialysis was determined by absorbance at 280 nm, using a theoretical 
extinction coefficient of 0.6 cm
2 
mg
-1
.  For experiments wherein the stabilizing effect of a 
binding ligand was tested, octanoic acid was added to the protein sample in 10 mM sodium 
phosphate buffer, pH 7.0, to a final concentration of 0.5 mM octanoic acid. 
 
5.2.2 Thermal stability monitored by circular dichroism spectroscopy 
Far UV circular dichroism (CD) was used to monitor the loss of alpha helical structure 
upon heating and to determine the apparent temperature midpoint of the thermal transition (Tm). 
Protein at a concentration of 0.1 mg/mL in a 1 mm pathlength cuvette was heated from 40 °C to 
90 °C in one degree increments with a one minute hold at each temperature. Spectra covering the 
200-250 nm range were collected at each temperature using a Chirascan Plus CD spectrometer 
(Applied Photophysics, Surrey, UK) with Peltier temperature control. At the end of each spectral 
scan, the target cell temperature (i.e., the temperature setting of the Peltier control) was 
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overwritten with the actual cell temperature at the time of the each measurement. Cell 
temperature was measured by a thermocouple.  Plots of circular dichroism signal at 222 nm 
versus actual cell temperature were used to estimate the apparent Tm with the Global Analysis 
software (Applied Photophysics, Surrey, UK). Each apparent Tm value represents the average of 
three separate thermal scans ± the standard deviation. 
 
5.2.3 Chaotrope denaturation monitored by intrinsic fluorescence 
The chaotrope perturbation method described previously
 32
 was used to determine the free 
energies of unfolding for HSA-GCSF under various solution conditions at 25 °C. To obtain the 
data for chaotrope-induced unfolding of the protein, HSA-GCSF at a concentration of 0.1 
mg/mL was incubated overnight at 25 °C in urea (0-10 M). After incubation, intrinsic 
fluorescence spectra were obtained. The protein was excited at 293 nm, and the emission spectra 
from 300-400 nm were recorded using an Aminco Bowman Series 2 fluorescence 
spectrophotometer (SLM Aminco, Urbana, Illinois). The center of spectral mass (CSM) of each 
emission spectrum was calculated using Equation 1 and plotted versus urea concentration.  
 
(1)      
     
   
 
 
In Equation 1, Fi is the fluorescence intensity at a given wavelength, vi. Plots of CSM values 
versus chaotrope concentration were then fit to a two-state unfolding model using a linear least-
squares fit to Equation 2 to calculate the free energies of unfolding (ΔGNU)
 33
. Equation 3 
represents the linear approximation for ΔGNU for chaotrope-induced denaturation
 33
.  
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(2)     
                             
     
  
 
       
     
  
 
 
 
(3)                         
 
In Equation 2, kN and kU are the slopes of the baselines of the native and unfolding states 
respectively, bN and bU are the intercepts of these baselines, Y0 is the center of spectral mass 
value T is temperature, and R is the molar gas constant. In Equation 3, [D] is the concentration of 
the chaotrope and m represents dΔGNU/d[D] (i.e., the sensitivity of ΔGNU to chaotrope 
concentration). ΔGNU(D) is the free energy of the unfolding with chaotrope present and 
ΔGNU(H20) is the free energy of unfolding at a zero chaotrope concentration.  
 
5.2.4 Osmotic second virial coefficients determined by static light scattering 
Static light scattering intensities of HSA-GCSF, either in buffer alone or with 0.5 mM 
octanoic acid or 150 mM NaCl, were measured at 25 °C using a Brookhaven light scattering 
system (Holtsville, NY) and an aperture set to 1.0 mm. For each solution condition, the 
scattering intensity at 90° from 633 nm incident light was measured for five samples ranging in 
protein concentration from 0.5-3 mg/mL. Prior to measurement, samples containing protein were 
filtered with a 0.1 μm inorganic filter (Whatman Anotop, Kent, UK), and the buffer was filtered 
with a 0.02 μm filter. The concentration of each sample was calculated from the A280 value 
measured post-filtration. The second osmotic virial coefficient (B22) was calculated from the 
scattering intensity at 90° using the virial expansion of the ideal osmotic pressure equation
 34 
represented by Equation 4: 
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(4)  
  
   
  
 
  
              
  
In equation 4, K is the optical constant, R90 is the excess Raleigh scatter at 90°, MW is the 
molecular weight and c is the protein concentration of the sample. 
The optical constant K is represented by equation 5: 
 
(5)    
     
         
    
   
  
where no is the solvent refractive index, dn/dc is the refractive index increment, NA is 
Avogadro’s number and λ is incident wavelength (633 nm). For these calculations, a dn/dc value 
of 0.185 was used
 35
. 
 
5.2.5 Zeta potential measurements 
 Electrophoretic mobilities were measured using the Malvern Zetasizer Nano ZS 
(Worcestershire, United Kingdom) and converted to zeta potentials using the Smoluchoski 
approximation to Henry’s equation (Equation 6) 36.  
(6)     
     
  
 
In Equation 6, μe is the electrophoretic mobility, η is the solution viscosity,   is the dielectric 
constant, ζ is the zeta potential and ks equals 1.5 in the Smoluchoski approximation
 36
. Protein 
samples at 25 °C and a concentration of 1 mg/mL were placed in disposable folded capillary cells 
(Malvern Instruments Ltd, Worcestershire, United Kingdom). Zeta potentials were measured 
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after a 20 second equilibration in the instrument and the values reported represent the average for 
three samples ± the standard deviation.   
The effective charge on the protein was calculated using the Debye-Hückel 
approximation (Equation 7)
 37
:  
(7)    
               ζ
 
 
where z is the effective charge,  r is the dielectric constant of the solution,  0 is the vacuum 
permittivity, rp is the effective sphere radius of the protein, k is the inverse Debye length and e is 
the elementary charge. The effective charge, z, can then be used to calculate the electrostatic 
contribution to B22, or the Donnan term, using Equation 8
 38
:  
(8)                    
  
   
        
 
where Mw is the molecular weight of the protein,  s is the solvent density and mions is the molal 
concentration of ions.  
 
5.2.6 Aggregation studies 
HSA-GCSF was incubated at 40 °C so that comparison could be made with GCSF 
aggregation data in the literature
 4
. 100 μL aliquots of 5 mg/mL protein were placed into 
polypropylene microcentrifuge tubes (Fisher Scientific, Pittsburgh, PA) that were sealed with 
Parafilm to prevent sample evaporation. Following incubation, samples were centrifuged for five 
minutes at 15400g to remove large particles and then analyzed by size exclusion chromatography 
(SEC). For the SEC analysis, a 3000Swxl gel sizing column (Tosoh Bioscience LLC, 
Montgomeryville, PA) was used in conjunction with a Beckman System Gold HPLC (Beckman 
Coulter, Brea, CA) and a Waters 717plus autosampler (Waters Technologies Corporation, 
Milford, MA). Peak areas were determined by integration using Bomem/Grams software version 
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7.00. Monomer concentrations were calculated from integrated peak area, and reaction rates 
were calculated from the slope of plots of monomer concentration versus time. The reported 
reaction rates represent the average of rate constants from three incubation experiments. Errors 
represent the standard deviation. To calculate the apparent reaction order, reaction rates were 
obtained for samples incubated at different initial protein concentrations. The reaction rates at the 
different initial concentrations were then used to calculate the reaction order by performing a 
natural log transformation on the rate equation: 
(7)  r = k[c]
x 
  
where r is the reaction rate, k is the rate constant and x is the apparent reaction order. The 
apparent reaction order is the slope of the plot of the natural log of the rate versus the natural log 
of the protein concentration and the reported error is ± the 95% confidence interval on the fit. 
 
5.3 Results 
5.3.1 Conformational stability  
Chaotrope-induced denaturation resulted in an unfolding profile for HSA-GCSF that 
appeared to be two-state, apparently with overlapping and cooperative unfolding of the HSA and 
GCSF domains (Figure 5-1). The free energy of unfolding (ΔGNU) values for HSA-GCSF in 
phosphate buffer alone, PBS or phosphate buffer with 0.5 mM octanoic acid at 25 °C are listed in 
Table 1. In 10 mM phosphate buffer and PBS, the free energy of unfolding values for the HSA-
GCSF fusion protein were very similar to the value of ΔGNU determined by earlier researchers 
for GCSF itself
 16
, and substantially higher than the previously determined value for HSA  
alone
 28
. Also, the presence of 0.5 mM octanoic acid increased the ΔGNU of HSA-GCSF by 
approximately10 kJ/mol.  
 108 
 
 
 
 
Figure 5-1: Representative urea-induced denaturation curves showing the center of spectral 
mass (CSM) versus urea concentration for HSA-GCSF alone (), with 150 mM NaCl () or 
with 0.5 mM octanoic acid (). Free energies of unfolding were calculated from the combined 
unfolding curves of three separate experiments.  
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During heating in 10 mM sodium phosphate at pH 7.0, only one unfolding transition was 
observed for HSA-GCSF (Figure 5-2). Addition of 0.5 mM octanoic acid increased the apparent 
Tm of this transition by approximately 8 °C, whereas addition of 150 mM NaCl increased the 
apparent Tm only slightly (Table 5-1). 
 
5.3.2 Colloidal stability 
In 10 mM sodium phosphate buffer at pH 7.0, the net protein-protein self interactions for 
HSA-GCSF were attractive, as indicated by the negative B22 value (Table 5-2). When 0.5 mM 
octanoic acid was added, there was no detectable change in the net self-interaction. However, 
addition of 150 mM sodium chloride decreased the attractive self-interaction. No changes in zeta 
potential were detected with the addition of 0.5 mM octanoic acid. In contrast, the addition of 
150 mM NaCl appeared to colloidally destabilize the system, as reflected in zeta potential values 
that were closer to zero than those for HSA-GCSF in phosphate buffer or phosphate buffer with 
0.5 mM octanoic acid (Table 5-2). The electrostatic contributions to the zeta potential are similar 
in phosphate buffer and phosphate buffer with octanoic acid. In PBS, the electrostatic 
contributions to the zeta potential are decreased (Table 5-2).  
 
5.3.3 Aggregation studies 
 Incubation of 5 mg/mL HSA-GCSF in 10 mM sodium phosphate at pH 7.0 and 40 °C 
resulted in an aggregation rate of 1.0 ± 0.1 μmol L-1 day-1. The presence of 0.5 mM octanoic acid 
did not affect the aggregation rate significantly (Table 5-3). When incubated with 150 mM 
sodium chloride, there was a large increase in HSA-GCSF aggregation rate as compared to that 
in phosphate buffer alone. However, the aggregation rate of HSA-GCSF in PBS was still lower  
 110 
 
 
 
Figure 5-2: Far UV CD signal at 222 nm as a function of temperature for HSA-GCSF (solid 
line) and HSA-GCSF in the presence of 0.5 mM octanoic acid (dashed line) in 10 mM sodium 
phosphate (pH 7.0). Addition of octanoic acid increases the onset temperature of unfolding and 
the Tm.  
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Protein Solution conditions (pH 7.0) Apparent Tm (°C) ΔGNU (kJ/mol) 
HSA-GCSF 10 mM sodium phosphate  60.1 ± 1.5  44.3 ± 6  
HSA-GCSF 10 mM sodium phosphate, 150 mM 
NaCl  
63.2 ± 1.5 43.4 ± 3.0  
HSA-GCSF 10 mM sodium phosphate, 0.5 mM 
octanoic acid 
68.6 ± 1.6 56.8 ± 6.9  
GCSF 10 mM sodium phosphate, 150 mM 
NaCl  
60.95 ± 2
#
 39.7 ± 2.1*, 41.9
 +
 
HSA 67 mM sodium phosphate, pH 7.4 59.65 ± 0.05
^
 17.2 ± 4.2
^
 
 
Table 5-1: Free energy of unfolding and Tm values for HSA-GCSF and GCSF in varying 
solution conditions. Values represent the average of three experiments ± the standard deviation. 
GCSF values at 25 °C are from #Krishnan et al. (2002), *Chi et al. (2003) 16, and +Raso, et al., 
2005. HSA values are from 
^
Kosa et al. (1998)
 28
.  
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Protein Solution 
Conditions 
B22 x 10
3
 
(mL mol g
-2
)  
Zeta potential 
(mV)  
B22electrostatic x 10
5
  
(mL mol g
-2
) 
(% of B22) 
HSA-
GCSF 
10 mM sodium 
phosphate, pH 7.0  
-0.35 ± 0.22 -12.5 ± 2.3 6.8 
(19.6%) 
HSA-
GCSF 
10 mM sodium 
phosphate, 0.5 mM 
octanoic acid, pH 
7.0 
-0.33 ± 0.41 -10.3 ± 2.0 4.5 
(13.5%) 
HSA-
GCSF 
10 mM sodium 
phosphate, 150 
mM NaCl, pH 7.0 
-0.03 ± 0.03 -6.1 ± 1.1 0.1 
(3.4 %) 
GCSF 10 mM sodium 
phosphate, pH 7.0  
-0.72 ± 0.45* N/D N/D 
GCSF 10 mM sodium 
phosphate, 0.5 mM 
octanoic acid, pH 
7.0 
2.34 ± 1.9* N/D N/D 
 
Table 5-2: B22 and zeta potential values for HSA-GCSF at pH 7.0 measured under different 
solution conditions, as well as the electrostatic contribution to the B22. B22 and zeta potential 
values represent the average of three experimental determinations ± the standard deviation. B22 
electrostatic values were calculated from the average B22 and zeta potential values. GCSF values 
are from Chi et al. (2003)
 16
. N/D signifies not determined. 
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Protein Solution conditions (pH 
7.0) 
Reaction rates 
(μmol L-1 day-1) 
Apparent 
reaction order 
HSA-GCSF 10 mM sodium phosphate  1.0 ± 0.1 0.80 ± 0.3  
HSA-GCSF 10 mM sodium phosphate, 
150 mM NaCl  
3.7 ± 1.0 
 
1.95 ± 0.4  
HSA-GCSF 10 mM sodium phosphate, 
0.5 mM octanoic acid 
1.2 ± 0.1 1.71 ± 0.1  
GCSF 10 mM sodium phosphate, 
150 mM NaCl  
7.3 ± 0.6* 2.17 ± 0.09* 
HSA 10 mM sodium phosphate 0
#
 N/D
#
 
 
Table 5-3: Aggregation behavior of HSA-GCSF at 5 mg/mL and GCSF, including reaction rates 
and apparent reaction orders for the given solution conditions. HSA-GCSF aggregation was 
measured at 40 °C. Reaction order values are the best fit to three combined experiments ± the 
95% confidence interval on the fit. *GCSF values are from Krishnan et al. (2002) and were 
measured at a concentration of 1 mg/mL and 37 °C. #The reaction rate for HSA was zero, within 
error and thus the apparent reaction order was not determined.  
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than aggregation rate of GCSF which was determined by Krishnan et al.
 39
 under the same 
conditions. The apparent reaction order (Table 5-3) for HSA-GCSF aggregation was close to first 
order in phosphate buffer alone. Addition of octanoic acid resulted in an aggregation reaction 
order closer to second order. In PBS at pH 7.0, the aggregation of HSA-GCSF was second order 
in protein concentration, which matches the previous findings for GCSF
 4
 (Table 5-3). 
 
5.4 Discussion 
Fusion protein domains, which are chosen for particular therapeutic reasons (e.g., 
increased circulation half-life, added functionality), may have very different individual 
conformational and colloidal stability properties compared to those of the overall fusion protein. 
Thus, finding solution conditions that adequately stabilize the entire protein may be difficult. 
Similar issues can be seen with large multi-domain proteins such as antibodies. The Fab and Fc 
antibody domains may respond differently to the same stress condition due to differences in their 
surface properties
 39, 40
. The Fab and Fc domains also exhibit differences in conformational 
stability, and the Fc domain may even exhibit two transitions due to the separate unfolding CH2 
and CH3 regions
 41, 42
. Aggregation and/or association of the intact antibody can thus be driven by 
the instability of a single domain
 40, 43
, with the overall stability behavior of the antibody 
corresponding more closely to the behavior of either the isolated Fab or Fc domains. There are 
several recent examples of this. In one case, the Fab region was responsible for the observed 
antibody self association
 43
. In another study, the aglycosylated Fc domain was shown to 
aggregate more rapidly than the glycosylated Fc domain. The aggregation of the aglycosylated 
antibody also increased in a similar manner to that of the aglycosylated Fc domain
 40
. Even 
within the IgG subclass, either the Fc or the Fab domain can drive aggregation for different IgG 
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molecules
 39, 44
, illustrating both the complexity of larger multi-domain proteins as well as the 
difficulties in making generalizations or predictions about the aggregation behavior. 
In the current study, the HSA-GCSF fusion protein aggregated more slowly than has 
previously been found for the therapeutic GCSF alone
 4
 in PBS at pH 7.0. This is likely due to 
the presence of the HSA domain in the fusion protein, as the aggregation of HSA alone was 
previously found to be so slow as to be undetectable at pH 7.0 and 50 °C during one month of 
incubation
 29
, in spite of its lower conformational stability. Even though HSA is less 
conformationally stable than GCSF (Table 1), it appears to confer some of its resistance to 
aggregation to the fusion protein, as GCSF aggregation has previously been detected at pH 7.0 
and 40 °C 16. Previous studies in multi-domain proteins support the observation that the least 
conformationally stable domain is not necessarily the most aggregation prone
 45
. The findings 
here are similar, with slower aggregation rates for the less conformationally stable HSA (ΔGNU = 
17.2 ± 4.2 kJ/mol)
 28
 compared to GCSF and HSA-GCSF which had higher free energies of 
unfolding of 39.7 ± 2.1 kJ/mol
 16
 and 44.3 ± 6 kJ/mol, respectively. 
The aggregation rate of HSA-GCSF in 10 mM phosphate buffer, pH 7.0 increased 
approximately three-fold with the addition of 150 mM sodium chloride. No large changes in 
HSA-GCSF conformational stability were detected in solutions containing 150 mM NaCl 
compared to 10 mM sodium phosphate buffer alone. In contrast, zeta potential measurements 
indicate that HSA-GCSF is colloidally destabilized in the presence of salt. Although B22 
measurements seem to indicate that the addition of salt shields attractive HSA-GCSF protein-
protein interactions (Table 2), the error associated with B22 measurements is much larger than 
that of the zeta potential measurements and is not statistically significant. Furthermore, while 
zeta potential measurements reflect the role of electrostatic interactions, B22 values include the 
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contributions from all of the interaction forces (e.g., hard sphere, Van der Waals, electrostatic)
 46
. 
The electrostatic component of the B22 is decreased with the addition of NaCl, from 19.6% of the 
total B22 to only 3.4% (Table 2). Taken together, the observations from the conformational 
stability studies and zeta potential measurements indicate that colloidal instability is the driving 
force for the aggregation observed in PBS. Further supporting this conclusion is previous work 
that showed the addition of NaCl increased GCSF net attractive protein-protein interactions as 
measured by static light scattering and also increased the rate of aggregation
 4, 16
. As apparent 
second order reactions were measured for both HSA-GCSF and GCSF
 4
 in PBS, and because the 
reaction rates were similar, we speculate that the aggregation of HSA-GCSF is driven by the 
GCSF domain under these conditions.  
The addition of octanoic acid, an HSA binding ligand
 31, 47,
 
48
, resulted in no change in the 
aggregation rate of 5 mg/mL HSA-GCSF, even though the conformational stability of the protein 
was increased under these conditions. No changes in HSA-GCSF colloidal stability were 
observed with the addition of octanoic acid (Table 2). This is in contrast to what was seen 
previously with HSA-hGH, where the addition of octanoic acid increased both conformational 
and colloidal stability of the fusion protein in addition to reducing aggregation rates
 29
. Addition 
of octanoic acid presumably increases the conformational stability of the HSA domain in the 
HSA-GCSF fusion protein. Since this increase occurs without a concomitant decrease in 
aggregation rate, it appears that the aggregation behavior of the fusion protein is dominated by 
the behavior of the GCSF domain, supporting the conclusions from the experiments in PBS.  
Although GCSF and hGH are fairly similar in structure (both are predominately alpha-
helical, and there is only approximately 3 kDa difference in molecular weight)
 15, 49
, HSA-GCSF 
exhibits different stability behavior compared to that seen previously for HSA-hGH in almost 
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every aspect, including intrinsic conformational stability, colloidal stability and propensity to 
aggregate
 29
. Only one unfolding transition is observed during HSA-GCSF denaturation by 
chaotropes, whereas two transitions are apparent for HSA-hGH
 29, 50
. The colloidal stabilities of 
the two proteins are different as well. At pH 7.0, HSA-hGH self interactions are repulsive
 29
 but 
HSA-GCSF self interactions are attractive. Although B22 values are not necessarily expected to 
be additive, one possible explanation for this observation could be the pI values of the individual 
domains. The pI of hGH is pH 5.0
 51
, whereas the pI values for both HSA (pH 5.8)
 52
 and GCSF 
(pH 6.1)
 16
 are approximately one pH unit closer to the solution condition pH 7.0.  This could 
lead to HSA-GCSF having decreased intermolecular charge-charge repulsive interactions 
compared to HSA-hGH. Furthermore, HSA-GCSF aggregates more rapidly than HSA-hGH in 
phosphate buffer at pH 7.0 (1.0 ± 0.1 μmol L-1 day-1 for GCSF versus 0.6 ± 0.1 μmol L-1 day-1 for 
HSA-hGH) and the measured HSA-GCSF aggregation was detected at 40 °C in the current 
study, whereas HSA-hGH aggregation was not detected until incubation at 50 °C 29. Whereas the 
HSA fusion protein aggregation behavior may be dominated by the non-HSA domain, clearly the 
behavior is different enough that each HSA fusion protein will likely require individually 
tailored conditions and the potential for a platform formulation approach is limited. 
 
5.5 Conclusions 
 The fusion of HSA to GCSF reduces the rate of aggregation of the therapeutic HSA-
GCSF compared to the rate of aggregation of GCSF itself. However, under the solution 
conditions tested, the overall aggregation rate and aggregation reaction order of the HSA-GCSF 
fusion protein are still more similar to those of GCSF than HSA. Because HSA-GCSF 
aggregation appears to be driven by the GCSF domain, the strategy of stabilizing HSA-GCSF via 
ligand binding to HSA does not reduce the rates of HSA-GCSF aggregation. This is in contrast 
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to previously reported results for another HSA fusion protein, HSA-hGH, where stabilizing the 
HSA domain via small molecule ligand binding reduced fusion protein aggregation rates. Thus, 
each HSA fusion protein may require individually tailored solution conditions to reduce 
aggregation.  
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CHAPTER 6 
 
CONCLUSIONS 
 
 
6.1 Fusion protein observations 
Fusion proteins can offer many benefits as a platform, including extended serum half-life 
or creation of a bi-functional molecule
 1, 2, 3
. These benefits, among others, make fusion proteins 
attractive drug candidates. However, these are complex molecules that may present formulation 
challenges. This thesis outlined some of the issues with fusion protein stability and potential 
methods to address those concerns and reduce overall protein aggregation.  
 One of the reasons for concern about the identification of stable fusion protein 
formulations is that these complex molecules combine two or more individual proteins/protein 
domains which did not co-evolve. Because the fusion domains did not co-evolve, the domains 
lack native stabilizing intra-domain interactions, making identification of solution conditions 
which adequately stabilize each domain potentially difficult.  
 Fusion domains may have very different conformational and colloidal stabilities. 
Although the colloidal stability of the domains is not expected to be predictive, differences in 
domain pI and domain net charge can still impact the overall stability of the fusion construct. 
Conformational stability of the individual domains in the fusion protein may more closely match 
the conformational stability of the individual domains, increasing the likelihood that formulation 
strategies to increase the conformational stability of the domain will work in the fusion as well.  
 This similarity in domain conformational stability between the original proteins and their 
stability as part of the fusion construct was seen in the case of the Fc-CTLA4 fusion protein. 
CTLA4 alone has a lower conformational stability than what has previously been reported for the 
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antibody Fc domain
 4
 and was one of the least conformationally stable domains in the protein, 
along with the CH2 domain which had been mutated in this particular protein. Conditions which 
destabilized the CTLA4 and CH2 domains resulted in a decreased activation energy for 
aggregation and an increased aggregation rate. Modifying protein-protein interactions to make 
them more repulsive did not reduce aggregation under solution conditions where the CTLA4 and 
CH2 domains were still destabilized. This indicates that conformational instabilities of the 
CTLA4 and CH2 domains are the driving force for aggregation of this protein during accelerated 
stability studies at elevated temperature.  
 Domain conformational instabilities, which contributed heavily to the aggregation of Fc-
CTLA4 during elevated temperature incubation studies, also drove the aggregation under 
different stress conditions. During freeze/thaw and agitation studies in buffer at pH 6.0 and at pH 
7.5, greater amounts of aggregation were observed at pH 6.0. Stress conditions ranged from 
fairly mild (i.e., 5 freeze thaw cycles, no monomer loss observed by SEC) to harsh (i.e., 6 hours 
agitation, approximately 20% initial monomer lost observed by SEC) with the same observation 
of greater aggregation in solution conditions at pH 6.0. This was true whether one was following 
aggregation by monitoring increase in particle count (in the case of freeze/thaw cycling) or by 
monitoring monomer loss as detected by SEC. Differences in the two pH conditions were 
observed was after 24 hours of storage. For samples that had undergone 5 freeze/thaw cycles, 
particle counts at pH 7.5 decreased while those at pH 6.0 did not, indicating that particles formed 
at pH 7.5 due to freeze/thaw stress are more reversible than those formed at pH 6.0. For the Fc-
CTLA4 fusion protein, increasing domain conformational stability results in the most stable 
formulation. 
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In the case of the HSA fusion proteins studied here (HSA-hGH and HSA-GCSF), the 
HSA domain was the least conformationally stable. However, unlike what was previously seen 
with the Fc-CLTA4, increasing the conformational stability of the least stable domain did not 
reduce aggregation. Binding octanoic acid, a small molecule ligand for HSA, to the fusion 
proteins increased the conformational stability of both proteins but the increased conformational 
stability did not seem to reduce aggregation. Although HSA-hGH aggregation was reduced with 
octanoic acid, the binding of the small molecule also increased repulsive protein-protein 
interactions and aggregation was reduced by shifting from pH 5 to pH 7. This shift from pH 5 to 
pH 7 increased HSA-hGH repulsive protein-protein interactions but did not seem to significantly 
increase the conformational stability. Binding of octanoic acid to HSA-GCSF did not cause any 
changes to protein-protein interactions and did not reduce aggregation. Thus it seems that HSA 
fusion protein aggregation is driven more by colloidal instabilities.  
Interestingly, HSA fusions are aggregating much faster than the HSA domain alone, even 
though HSA is the least conformationally stable domain in each fusion protein. The aggregation 
of each fusion seems to be more close to that of the active molecule alone, either hGH or GCSF. 
Even though HSA alone is resistant to aggregation, this does not result in HSA fusion constructs 
that also are resistant to aggregation.  
Overall, the two HSA fusion proteins studied here are fairly similar. The molecular 
weight values are close: approximately 86 kDa for HSA-GCSF
 5, 6, 7
 and approximately 89 kDa 
for HSA-hGH
 3
,. Both combine a smaller alpha helical protein with HSA to produce to fusion 
product and the pI values for the fusion partners aren’t wildly different (approximately 6.1 for 
GCSF
 5
 and 5.1 for hGH
 8
). However, the resulting fusion products have very different stability 
and aggregation profiles, as outlined above and in previous chapters. Given that such different 
127 
 
aggregation profiles were obtained for these two products, it is unlikely that HSA fusions with 
even more dissimilar fusion partners would behave similarly to either of the proteins previously 
studied here.  
This faster aggregation of the HSA fusion proteins does not necessarily indicate that HSA 
fusions are not a viable strategy to pursue for the extension of circulation half-life. Since the 
aggregation studies are conducted under elevated stress conditions, the overall HSA fusion 
protein aggregation under real time storage conditions may still be acceptable and meet the 
storage criteria. However, a therapeutic protein which is unstable and has difficulty meeting the 
aggregation criteria during real time storage is likely not a good candidate for a HSA fusion 
protein. In cases like those, if there is a need for extended serum half-life, other strategies should 
be explored.  
That being said, there are currently no FDA approved HSA fusion protein products on the 
market. Human Genome Sciences submitted a BLA for the treatment of hepatitis using an HSA-
Interferon alpha (IFNα) fusion, but the application was withdrawn prior to a decision by the 
FDA, according to their corporate website. The reasons cited for the withdrawal of the 
application were safety concerns related to the dosing schedule and the company indicated they 
may refile at a future date. However, HSA-IFNα is not currently listed as a product or pipeline 
candidate on the HGS corporate website, www.hgsi.com, as of July 10
th
, 2011.   
 
6.2 Future of the ligand binding approach for domain stabilization  
Although the addition of a small molecule ligand was shown to reduce the aggregation in 
some instances (e.g. HSA-hGH aggregation), there remain some challenges for future work. If 
this approach is to be further pursued as a stabilizing strategy, there is a need to move beyond 
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exploring the ligand binding approach as a proof-of-concept and to start addressing the concerns 
involved as well. Protein formulation does not happen in a vacuum. Regardless of how stable of 
a formulation one is able to design, if the formulation components are not safe for the patient, the 
formulation is useless. Thus one would need to identify safe, FDA approved small molecules for 
use as stabilizing ligands.  
In the case of dialysis procedures that involve the use of HSA, it has been shown that 
patients are also exposed to octanoic acid
 9
. Octanoic acid is used to stabilize HSA during the 
heat treatment step in production and is often present in commercial formulations at an octanoic 
acid: HSA molar ratio of 5.4:1. Increases in the concentration of octanoic acid in the patients’ 
bloodstreams were observed during treatment. This is a concern because octanoic acid has been 
shown to have a direct involvement in the pathogenesis of liver failure
 9
. Even though octanoic 
acid is present in the commercial HSA formulations, one might want to investigate safer ligands 
and reduce octanoic acid exposure when possible. This could be especially important in the case 
of the HSA-interferon alpha fusion protein which was investigated for the treatment of hepatitis 
C. In that case, avoiding excipients which may contribute to liver failure would be of utmost 
importance and octanoic acid is not likely to be a good choice, regardless of its ability to reduce 
aggregation of some HSA fusion proteins.  
 There are further questions involved depending on which domain of the fusion protein is 
targeted for selective stabilization. If one is binding a molecule to the active domain of the 
fusion, what might the impact be in the body? This is not likely to be a concern for selective 
stabilization of HSA, since the HSA domain is not designed to be an active part of the 
therapeutic molecule but rather just a way to extend serum half life. However, this may be 
different in the case of the Fc fusion protein constructs. The Fc domain has a relatively high 
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conformational stability
 4
 making it likely that the active domain would be the less 
conformationally stable domain, as is the case with the Fc-CTLA4 fusion. Additionally, in some 
cases the biological activity of the Fc domain is desirable, such as the ability to induce antibody 
dependent cell mediated cytotoxicity or trigger the release of inflammatory cytokines. The 
choice of a small molecule ligand must reflect these concerns and care must be taken to identify 
a ligand which is not bound too strongly such that the activity and efficacy of the therapeutic 
protein is affected.  
 
6.3 Final recommendations 
 
The results of the studies contained herein indicate that fusion proteins are very complex 
molecules and that understanding individual domain behavior or the behavior of a similar fusion 
protein is unlikely to allow one to make predictions about formulating a new fusion protein. Each 
fusion protein requires individual study and we have yet to identify any potential shortcuts in the 
development of fusion protein formulations.  
In the case of the Fc-CTLA4 fusion, the domain which was driving the aggregation 
behavior is unlikely to be the conserved domain in any future fusion proteins. Thus strategies 
aimed at stabilizing this protein may have limited utility in other cases. Furthermore, Fc domains 
in other fusions may require the Fc biological activity and lack the mutations that may have 
reduced CH2 stability and contributed to the aggregation. One could also imagine a scenario 
where a Fc domain with mutations in the CH2 region is partnered with a more conformationally 
stable protein in the fusion construct and that having the more stable fusion partner and the CH3 
domain on either side of the mutated CH2 domain could lead to increases in CH2 conformational 
stability.  
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Even with the conserved HSA domain, the two HSA fusions aggregated very differently, 
as mentioned above. Ligand binding did not appear to reduce aggregation in the manner 
hypothesized initially, and did not work as a method to reduce aggregation across the HSA 
fusion protein class. As mentioned in the case of the Fc fusions, it is likely that each HSA fusion 
protein must be investigated independently in order to develop the most stable formulation.  
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